var title_f40_5_41040="Monilethrix hair shaft";
var content_f40_5_41040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Monilethrix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Elliptical nodes are visible in these hair shafts from a patient with monilethrix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41040=[""].join("\n");
var outline_f40_5_41040=null;
var title_f40_5_41041="Boy with measles";
var content_f40_5_41041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57803%7EID%2F57093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57803%7EID%2F57093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Boy with measles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 143px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Measles exanthem",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blanching erythematous rash with some confluent areas on the trunk in a patient with measles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright Dr. Michael Bennish; reproduced with his permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41041=[""].join("\n");
var outline_f40_5_41041=null;
var title_f40_5_41042="Gentian violet: Drug information";
var content_f40_5_41042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gentian violet: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/19/3380?source=see_link\">",
"    see \"Gentian violet: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/61/26578?source=see_link\">",
"    see \"Gentian violet: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Superficial skin or mucocutaneous infection:",
"     </b>",
"     Topical: Apply to affected area once or twice daily. Solutions diluted to 0.25% to 0.5% may be less irritating. Solutions diluted to 0.01% have been recommended for use in closed cavities.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F176036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/61/26578?source=see_link\">",
"      see \"Gentian violet: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Superficial skin or mucocutaneous infection:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 1% (59 mL); 2% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5184555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Apply with cotton-tipped applicator directly to affected area. Do not cover with bandage. If applied to mucous membranes inside mouth, do not allow to be swallowed. Do not use in the eyes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous or mucocutaneous infections caused by",
"     <i>",
"      Candida albicans",
"     </i>",
"     and other superficial skin infections; external treatment of minor abrasions or cuts",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6052748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Gentian violet may be confused with gentamicin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Necrotic skin reactions, staining, vesicle formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Esophagitis, gastrointestinal irritation, ulceration of mucous membranes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hemorrhagic cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Keratoconjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis, laryngitis, laryngeal obstruction, tracheitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic contact dermatitis, sensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gentian violet or any component of the formulation; ulcerated areas",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occur, or if condition worsens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Staining: Will stain skin and clothing. Application to ulcerative lesions may result in tattooing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes. Not for self-medication (OTC use) for serious burns or deep puncture wounds",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gentian Violet External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (59 mL): $6.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (59 mL): $13.33",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical antiseptic/germicide effective against some vegetative gram-positive bacteria, particularly",
"     <i>",
"      Staphylococcus",
"     </i>",
"     sp, and some yeast; it is much less effective against gram-negative bacteria and is ineffective against acid-fast bacteria",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Balabanova M, Popova L, Tchipeva R, &ldquo;Dyes in Dermatology,&rdquo;",
"      <i>",
"       Clin Dermatol",
"      </i>",
"      , 2003, 21(1):2-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/5/41042/abstract-text/12609582/pubmed\" id=\"12609582\" target=\"_blank\">",
"        12609582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8749 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.22.229.50-9649136F8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41042=[""].join("\n");
var outline_f40_5_41042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176039\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176033\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176036\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176034\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176028\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176015\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5184555\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176029\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052748\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176037\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176031\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176019\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299399\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176024\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265830\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323170\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176018\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/19/3380?source=related_link\">",
"      Gentian violet: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/61/26578?source=related_link\">",
"      Gentian violet: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_5_41043="Weber and Rinne tests";
var content_f40_5_41043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Evaluation of hearing loss, Weber and Rinne tests",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <b>",
"     Weber test:",
"    </b>",
"    Place the base of a struck tuning fork on the bridge of the forehead, nose or teeth. In a normal test there is no lateralization of sound. With unilateral conductive loss, sound lateralizes towards affected ear. With unilateral sensorineural loss, sound lateralizes to the normal or better-hearing side.",
"    <br>",
"     <b>",
"      Rinne test:",
"     </b>",
"     Place the base of a struck tuning fork on the mastoid bone behind the ear. Have the patient indicate when sound is no longer heard. Move fork (held at base) beside ear and ask if now audible. In a normal test, AC &gt; BC; patient can hear fork at ear. With conductive loss, BC &gt; AC;patient will not hear fork at ear.",
"     <div class=\"footnotes\">",
"      AC: air conduction; BC: bone conduction.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41043=[""].join("\n");
var outline_f40_5_41043=null;
var title_f40_5_41044="Coronal organ nasal view";
var content_f40_5_41044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Coronal whole organ section through the nasal vestibule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright &copy; 1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41044=[""].join("\n");
var outline_f40_5_41044=null;
var title_f40_5_41045="Risedronate: Patient drug information";
var content_f40_5_41045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Risedronate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     see \"Risedronate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actonel&reg;;",
"     </li>",
"     <li>",
"      Atelvia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actonel&reg;;",
"     </li>",
"     <li>",
"      Actonel&reg; DR;",
"     </li>",
"     <li>",
"      Apo-Risedronate&reg;;",
"     </li>",
"     <li>",
"      Dom-Risedronate;",
"     </li>",
"     <li>",
"      Novo-Risedronate;",
"     </li>",
"     <li>",
"      PMS-Risedronate;",
"     </li>",
"     <li>",
"      ratio-Risedronate;",
"     </li>",
"     <li>",
"      Riva-Risedronate;",
"     </li>",
"     <li>",
"      Sandoz-Risedronate;",
"     </li>",
"     <li>",
"      Teva-Risedronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11442205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Paget's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to risedronate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A swallowing tube (esophagus) that is not normal, low calcium levels, or trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701337",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to stand or sit up for 30 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have GI (gastrointestinal) disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone, joint, or muscle pain may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A broken leg may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the jaw bone may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad groin or thigh pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Twitching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695915",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with plain water only. Avoid taking with mineral water or other drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drink or eat for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not lie down for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug works best when used with calcium/vitamin D and weight-bearing workouts like walking or PT (physical therapy).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705419",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Fast release:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach before breakfast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3008563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after breakfast.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11026 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3A9BE56C6A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41045=[""].join("\n");
var outline_f40_5_41045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218582\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218583\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442205\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025111\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025110\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025115\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025116\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025118\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025113\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025114\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025119\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025120\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=related_link\">",
"      Risedronate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_5_41046="Buprenorphine and naloxone: Pediatric drug information";
var content_f40_5_41046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Buprenorphine and naloxone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/51/24375?source=see_link\">",
"    see \"Buprenorphine and naloxone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/13/17622?source=see_link\">",
"    see \"Buprenorphine and naloxone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13143399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Opioid Partial Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/51/24375?source=see_link\">",
"      see \"Buprenorphine and naloxone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sublingual tablets and film contain a free-base ratio of buprenorphine:naloxone of 4:1. Doses based on buprenorphine content; titrate to appropriate effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Opioid dependence, maintenance treatment:",
"     </b>",
"     Sublingual: Adolescents &ge;16 years (sublingual tablets) and Adults (sublingual film or sublingual tablets):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction: Not recommended; initial treatment should begin using buprenorphine sublingual tablets (see buprenorphine monograph)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance: Target dose: 16 mg/day as a single daily dose; dosage should be adjusted in increments of 2 mg or 4 mg to a dose that adequately suppresses opioid withdrawal; usual range: 4-24 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Combination product for maintenance and for unsupervised therapy (if patient&rsquo;s clinical stability permits)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternate dosing (Center for Substance Abuse Treatment, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Induction (for patients  dependent on",
"     <b>",
"      short-acting",
"     </b>",
"     opioids and whose last dose of opioids was &gt;12-24 hours prior to induction):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Day 1: Initial: 4 mg; may repeat dose after &gt;2 hours if withdrawal symptoms not relieved; Day 1 maximum daily dose: 8 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Day 2 :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	If no withdrawal symptoms, repeat total daily dose from Day 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	If withdrawal symptoms are present, increase Day 1 dose by 4 mg; if withdrawal symptoms not relieved after &gt;2 hours, may administer 4 mg; Day 2 maximum daily dose: 16 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Subsequent induction days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	If withdrawal symptoms are not present, daily dose is established (stabilization dose).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &bull;	If withdrawal symptoms are present, increase dose in increments of 2 mg or 4 mg each day as needed for symptom relief. Target daily dose by the end of the first week: 12 mg or 16 mg/day; maximum daily dose: 32 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stabilization: Usual dose: 16-24 mg/day; maximum dose: 32 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Switching between sublingual tablets and sublingual film:",
"     </b>",
"     Same dosage should be used as the previous administered product.",
"     <b>",
"      Note:",
"     </b>",
"     Potential for greater bioavailability with the sublingual film compared to the sublingual tablet exists; monitor closely for either over- or underdosing when switching patients from one formulation to another.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Moderate to severe impairment: Dosage adjustments recommended; however, no specific dosage adjustment recommendations provided by manufacturer; monitor patients closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Film, sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suboxone&reg;: Buprenorphine 2 mg and naloxone 0.5 mg (30s); buprenorphine 4 mg and naloxone 1 mg (30s); buprenorphine 8 mg and naloxone 2 mg (30s); buprenorphine 12 mg and naloxone 3 mg (30s) [lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, sublingual: Buprenorphine 2 mg and naloxone 0.5 mg; buprenorphine 8 mg and naloxone 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suboxone&reg;: Buprenorphine 2 mg and naloxone 0.5 mg [DSC]; buprenorphine 8 mg and naloxone 2 mg [lemon-lime flavor] [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Sublingual tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F143159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prescribing of tablets for opioid dependence is limited to physicians who have met the qualification criteria and have received a DEA number specific to prescribing this product. Tablets will be available through pharmacies and wholesalers which normally provide controlled substances.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10815685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sublingual film: An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225677.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM225677.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual film: Film should be placed under the tongue. Keep under the tongue until film dissolves completely; film should not be chewed, swallowed, or moved after placement. If more than 1 film is needed, the additional film should be placed under the tongue on the opposite side from the first film to minimize overlapping as much as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual tablets: Place tablet under the tongue until dissolved; do not swallow. If  2 or more tablets are needed per dose, all tablets may be placed under the tongue at once, or 2 tablets may be placed under the tongue at a time; to ensure consistent bioavailability, subsequent doses should always be taken the same way.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of opioid dependence as part of a complete plan that includes counseling and psychosocial support (Sublingual tablet: FDA approved in ages &ge;16 years and adults; Sublingual film: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potential for over- or underdosing when switching among various formulations and between strengths of the sublingual films:",
"       <b>",
"        Not all strengths of sublingual tablets and films are bioequivalent to one another.",
"       </b>",
"       In addition, systemic exposure between the various strengths of sublingual films may be different; pharmacists should not substitute one or more film strengths for another (eg, dispense three 4 mg films for one 12 mg film, or vice-versa) without physician approval. Any patient switching between sublingual tablet and sublingual film formulation or between one or more strengths of the sublingual films should be monitored for over- or underdosing.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F143162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, erythema (oral mucosa; film), glossodynia (film), oral hypoesthesia (film), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to buprenorphine, naloxone, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with adrenal insufficiency (Addison&rsquo;s disease); biliary tract disease; pancreatitis; CNS depression/coma; acute alcoholism; delirium tremens; hypothyroidism (myxedema); severe liver, pulmonary or renal impairment; urinary stricture; prostatic hypertrophy; psychosis; or seizures and in children and debilitated patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Buprenorphine may cause CNS depression which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving); use caution when combining with other CNS depressants (eg, centrally acting antiemetics, general anesthetics, phenothiazines, sedative-hypnotics) due to additive CNS effects. If combination therapy is needed, consider dosage reduction of one or both agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Respiratory depression may occur; use with extreme caution in patients with respiratory diseases including asthma, emphysema, COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, other obstructive pulmonary disease, kyphoscoliosis, or other skeletal disorder which may alter respiratory function. Naloxone may be used in the management of respiratory depression, but higher doses and repeated administration may be necessary; mechanical ventilation may be required. Coma and death resulting from respiratory depression has been reported; many reports are associated with misuse by self-injection in combination with benzodiazepines and other CNS depressants including alcohol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May increase ICP; use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure. May cause hypotension; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Buprenorphine may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Physical and psychological dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms;  compared to full-opioid agonists, withdrawal from buprenorphine may be milder and may be delayed in onset; narcotic antagonist activity of buprenorphine may precipitate acute narcotic withdrawal in opioid-dependent individuals. Naloxone may precipitate intense withdrawal symptoms in patients addicted to opiates when administered before the opioid effects have subsided, or if misused parenterally in opioid-dependent individuals. Infants born to women physically dependent on opioids, including buprenorphine, will also be physically dependent and may experience respiratory difficulties or opioid withdrawal symptoms (neonatal abstinence syndrome). Symptoms of opiate withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, tremors, or vomiting; onset of symptoms ranged from day 1 to day 8 of life, most occurring on day 1 of life in infants of women receiving buprenorphine sublingual tablets during pregnancy; rare cases of convulsions (with one case of apnea and bradycardia) have also been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     High potential for abuse; healthcare providers should be alert to problems of abuse, misuse, and diversion. Oral buprenorphine is not approved for management of pain; deaths have been reported in opioid-naive patients receiving oral buprenorphine for analgesia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Hepatitis and other hepatic events have been reported in patients receiving buprenorphine for the treatment of opioid dependence; infection with viral hepatitis, concomitant use of potentially hepatotoxic drugs, pre-existing liver enzyme abnormalities, and ongoing drug use may have contributed to liver abnormalities. Monitor liver function tests in all patients prior to and during therapy. Hypersensitivity reactions, including bronchospasm, angioneurotic edema, and anaphylactic shock have also been reported. There is a potential for greater bioavailability with the sublingual film compared to the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another. Keep out of the reach of children and discard any open units properly; contains an amount of medication that can be fatal to children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Buprenorphine. Management: Advise patients receiving buprenorphine about the increased risk of CNS depression if they consume alcohol.  Consider alternatives to buprenorphine for opioid addiction treatment in patients who are dependent on alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Management: Avoid this combination in patients un-boosted atazanavir due to possible decreased atazanavir concentrations.  This combination is not contraindicated in patients also receiving ritonavir, but monitoring for buprenorphine toxicity is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Buprenorphine. Boceprevir may increase the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F143138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdrawal has been reported in infants of women receiving buprenorphine during pregnancy. Onset of symptoms ranged from day 1 to day 8 of life, most occurring on day 1.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptoms of withdrawal, respiratory rate, mental status, blood pressure; liver function tests (baseline and periodically during therapy)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13796275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: Buprenorphine: 100 minutes; Naloxone: No clinically significant effect when administered sublingually",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: High variability among patients, but low variability within each individual patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Buprenorphine: ~96%; Naloxone: ~45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Poor GI bioavailability; swallowing results in",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      5",
"     </sub>",
"     the potency compared to taking sublingually. Potential for greater bioavailability with sublingual film compared to sublingual tablet. Although pharmacokinetics were similar between the sublingual formulations, bioequivalence is variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Film: Buprenorphine: 24-42 hours; Naloxone: 2-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/13/17622?source=see_link\">",
"      see \"Buprenorphine and naloxone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of this medication. Read this guide for details on proper storage, administration, and disposal of sublingual tablets and film, as well as instructions about overdose management. Keep out of the reach of children and discard any open units properly; contains an amount of medication that can be fatal to children. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause postural hypotension (use caution when changing positions from lying or sitting to standing); avoid alcohol, sedatives, benzodiazepines, tranquilizers, and antidepressants; report the use of other prescription and nonprescription medications to your physician and pharmacist. May be habit-forming; use exactly as directed; do not increase dose or frequency; do not discontinue abruptly, dose should be tapered to prevent withdrawal. May cause dry mouth.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Naloxone has been added to the formulation to decrease the abuse potential of dissolving tablets or film in water and using as an injection (precipitation of severe withdrawal would occur in opioid dependent patients if the tablets or film were misused in this manner).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Center for Substance Abuse Treatment, \"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration,\" 2004.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12919 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41046=[""].join("\n");
var outline_f40_5_41046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13143399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051406\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051399\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143130\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143116\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143159\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217370\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10815685\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051410\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051402\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051409\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977973\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143162\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051413\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051398\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051397\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298908\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143123\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143125\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143138\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051405\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051396\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13796275\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051412\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051404\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051414\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12919|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/51/24375?source=related_link\">",
"      Buprenorphine and naloxone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/13/17622?source=related_link\">",
"      Buprenorphine and naloxone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_5_41047="Inverted papilloma Light";
var content_f40_5_41047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72164&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Inverted papilloma of the paranasal sinus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power (left panel) and high power (right panel) photomicrographs of inverted papillomas, which usually arise from the lateral nasal wall or paranasal sinuses. They may be entirely endophytic, or they may also have an exophytic component. In contrast to fungiform papillomas, they have malignant potential. Despite differences in behavior, fungiform and inverted papillomas have a similar lining, consisting of nonkeratinized squamous, mucinous and surface ciliated cells. Note the characteristic microabcesses (black arrow, right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41047=[""].join("\n");
var outline_f40_5_41047=null;
var title_f40_5_41048="Stress echocardiography: Indications, imaging techniques and safety";
var content_f40_5_41048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress echocardiography: Indications, imaging techniques and safety",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Alexis Beatty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41048/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/5/41048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography enables dynamic evaluation of cardiac structure and function at rest and during stress provoked by exercise or a pharmacologic agent. Two-dimensional echocardiographic imaging performed during or immediately after stress is used primarily to detect the presence (or absence) and extent of ischemia secondary to obstructive coronary artery disease and to measure or estimate overall ventricular systolic function. In addition, Doppler echocardiographic imaging performed during or after exercise stress allows for evaluation of valvular function, pulmonary artery pressure, and left ventricular diastolic function.",
"   </p>",
"   <p>",
"    The two major types of stress echocardiography are exercise (treadmill or bicycle) stress echocardiography and pharmacologic (predominantly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) stress echocardiography. The indications for stress echocardiography, along with the imaging technique and safety of the procedure, will be discussed here. Details of specific stress echocardiography protocols along with the advantages and disadvantages of stress echocardiography as compared to other stress modalities are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=see_link\">",
"     \"Protocols for stress echocardiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Stress test options'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing is a common procedure with a variety of indications. Most commonly, however, stress testing is performed to estimate the likelihood of obstructive coronary artery (CAD) in patients who present with symptoms suggesting this diagnosis, or to estimate the ischemic burden and the prognosis in a patient with known CAD. The indications for stress testing are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link&amp;anchor=H20#H20\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Indications for diagnostic non-invasive testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several specific indications for stress echocardiography as noted in the 2007 American Society of Echocardiography (ASE) stress echocardiography guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk stratification for patients with known or suspected coronary artery disease. The presence and extent of ischemic myocardium, as well as dysfunctional but viable (ie, hibernating) myocardium, can be evaluated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=see_link\">",
"       \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dyspnea of possible cardiac origin. Exercise echocardiography may be helpful in some cases when data from the resting echocardiogram is not sufficient to make a diagnosis.",
"     </li>",
"     <li>",
"      Pulmonary hypertension. Pulmonary artery systolic pressure can be estimated at rest and with exercise.",
"     </li>",
"     <li>",
"      Mitral stenosis. Stress echocardiography is indicated in asymptomatic patients with echocardiographically severe lesions as well as for patients with symptoms disproportionate to resting Doppler hemodynamics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link\">",
"       \"Medical management and indications for intervention in mitral stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=see_link\">",
"       \"Echocardiographic evaluation of the mitral valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mitral regurgitation. Exercise stress testing may aid in evaluation of symptoms including change in exercise tolerance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link\">",
"       \"Overview of the management of chronic mitral regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=see_link\">",
"       \"Echocardiographic evaluation of the mitral valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic stenosis. Exercise testing should NOT be performed in patients with symptomatic aortic stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/2\">",
"       2",
"      </a>",
"      ]. However, there are circumstances in which stress echocardiography may be reasonable in patients with aortic stenosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=see_link&amp;anchor=H14#H14\">",
"       \"Protocols for stress echocardiography\", section on 'Protocols for specific indications'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low gradient aortic stenosis:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      stress echocardiography may help distinguish true severe aortic stenosis from primary left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=see_link&amp;anchor=H19#H19\">",
"       \"Protocols for stress echocardiography\", section on 'Aortic stenosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35047?source=see_link\">",
"       \"Low gradient aortic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asymptomatic aortic stenosis: Low level or symptom-limited exercise stress testing may be helpful in documenting asymptomatic status, establishing safe limits for exercise, detecting arrhythmias, and timing surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy. Stress echocardiography in patients with hypertrophic cardiomyopathy and suspected left ventricular outflow tract (LVOT) obstruction is useful to document exercise tolerance, symptoms, detect a change in LVOT gradient or mitral regurgitation with or immediately after exercise and to seek stress-provoked arrhythmias. Details regarding the use of stress echocardiography in patients with hypertrophic cardiomyopathy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Exercise testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the 2007 stress echocardiography guidelines, several professional societies jointly issued Appropriate Use Criteria for Echocardiography, which delineates the appropriateness, uncertainty, or inappropriateness of echocardiography, including stress echocardiography, under differing clinical circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/3\">",
"     3",
"    </a>",
"    ]. The 2011 Appropriate Use Criteria for Echocardiography evaluated and rated the appropriateness of stress echocardiography in 87 specific circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMAGING TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Two-dimensional stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Society of Echocardiography (ASE) guidelines recommend tissue harmonic imaging for stress echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result of improvements in echocardiographic equipment, technically adequate studies can be obtained in over 90 percent of patients. The baseline (resting) echocardiogram obtained prior to stress should include a screening assessment of ventricular function, chamber sizes, wall thicknesses, aortic root diameter, and gross valvular structure and function, unless these have already been evaluated. Baseline and stress images are acquired in a variety of standard echocardiographic windows, including apical, parasternal, and subcostal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. Imaging with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress and bicycle exercise imaging is performed during stress testing, while imaging accompanying treadmill exercise occurs immediately after cessation of exercise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4662?source=see_link&amp;anchor=H10#H10\">",
"     \"Echocardiography essentials: Physics and instrumentation\", section on 'Second harmonic imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14167?source=see_link\">",
"     \"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interpretation of two-dimensional images",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two-dimensional echocardiographic image interpretation generally focuses on endocardial excursion and wall thickening, which in most instances are qualitatively evaluated. Validation and simplification of quantitative analysis methods may enable widespread use of these techniques in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various professional society recommendations for chamber quantification have suggested either a 16- or 17-segment model for left ventricular regional wall motion analysis (",
"    <a class=\"graphic graphic_figure graphicRef55855 \" href=\"mobipreview.htm?1/21/1360\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64968 \" href=\"mobipreview.htm?25/55/26487\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Function in each segment is graded &mdash; normal, hyperdynamic, hypokinetic, akinetic, dyskinetic, or aneurysmal &mdash; at rest and with stress. In addition, global left ventricular shape, cavity size, and contractility is evaluated. Images from various stages of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    or bicycle ergometry should be compared to maximize sensitivity for detection of coronary disease. The use of digitized cine-loop display systems, with which baseline and stress images can be compared side-by-side, has improved off-line analysis and detection of induced abnormalities in endocardial motion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14167?source=see_link\">",
"     \"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main goal of stress two-dimensional echocardiography is to compare global and regional left ventricular systolic function at rest and after (or with) peak exercise. Detection of segmental left ventricular dysfunction is useful in diagnosing and localizing obstructive coronary artery disease (",
"    <a class=\"graphic graphic_figure graphicRef55855 \" href=\"mobipreview.htm?1/21/1360\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61847 \" href=\"mobipreview.htm?21/25/21904\">",
"     figure 3",
"    </a>",
"    ). The normal left ventricle becomes hypercontractile and cavity size is smaller during exercise. The development of reduced segmental wall motion, decreased wall thickening, decreased global left ventricular ejection fraction, or increased left ventricular end-systolic volume during exercise suggests hemodynamically significant coronary artery stenoses supplying the abnormal segments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography enables identification of dysfunctional but viable (ie, hibernating) myocardial segments. In segments that have resting dysfunction but are viable (hibernating or stunned), low-dose dobutamine infusion leads to improved contractility. The 2007 ASE guidelines recommend that diagnosis of viability requires improvement by at least one grade in two or more segments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1\">",
"     1",
"    </a>",
"    ]. As dobutamine dose is increased, a biphasic response is detected if segmental motion improves at low dose and then deteriorates at a higher dose to a level of dysfunction that is worse than it was at rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. Such a response is highly specific for identifying a dysfunctional hibernating segment that is served by a stenotic artery. The highest sensitivity for viability detection is obtained by identification of improvement with low-dose dobutamine; highest specificity is achieved when a biphasic response occurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of right ventricular response to stress is also useful. Right ventricular free wall systolic dysfunction or lack of increase in tricuspid annular plane excursion during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress are indicators of right coronary or multivessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Use of contrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbubble ultrasound contrast agents can enhance left ventricular endocardial border definition during exercise and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography. Though the administration of a contrast agent requires intravenous access, use of the contrast agent increases the number of interpretable LV wall segments, improves the accuracy of less experienced readers, enhances diagnostic confidence, and reduces the need for additional noninvasive tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. The 2007 American Society of Echocardiography (ASE) stress echocardiography guidelines and 2008 ASE contrast guidelines recommend that contrast agents be used when two or more segments are not well visualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical characteristics suggesting the need for contrast during stress echocardiography include older age, male sex, smoking, presence of multiple coronary artery disease risk factors, higher body mass index, chronic lung disease, referral for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress, history of coronary artery disease, and abnormal baseline electrocardiogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/24\">",
"     24",
"    </a>",
"    ]. In our clinical practice we individualize need for contrast depending on image quality and ability to view the endocardial border.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Doppler stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler echocardiography enables measurement of flow velocities and pressure gradients across heart valves. Because Doppler recordings display instantaneous changes in these parameters, this is an excellent technique for the study of hemodynamic response to exercise or pharmacologic stress.",
"   </p>",
"   <p>",
"    Perhaps most importantly, continuous-wave Doppler echocardiography permits the calculation of pulmonary artery systolic pressure at rest and during exercise by evaluation of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/25\">",
"     25",
"    </a>",
"    ]. Technically suboptimal right heart Doppler signals can usually be improved by the intravenous injection of agitated saline. Technically suboptimal left heart Doppler signals can usually be improved by the use of intravenous injection of left-sided echo contrast agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with chronic pulmonary disease, primary pulmonary hypertension, or secondary pulmonary hypertension due to congenital heart disease, a rapid and exaggerated rise in pulmonary artery systolic pressure during exercise suggests pulmonary vascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with left ventricular dysfunction or significant mitral stenosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      regurgitation may have marked increases in pulmonary artery pressure with exercise. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=see_link&amp;anchor=H17#H17\">",
"       \"Protocols for stress echocardiography\", section on 'Mitral stenosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=see_link&amp;anchor=H18#H18\">",
"       \"Protocols for stress echocardiography\", section on 'Mitral regurgitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evolving technologies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12182096\">",
"    <span class=\"h3\">",
"     Evaluation for resynchronization therapy by stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with left ventricular systolic dysfunction and NYHA Class III or IV heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), evidence of dyssynchrony on exercise stress echocardiography has been shown to better predict response to cardiac resynchronization therapy than dyssynchrony on resting echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography may help unmask ventricular dyssynchrony by increasing contractility in viable myocardium and predict response to cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, global or regional contractile reserve on exercise stress echocardiography or dobutamine echocardiography predicts response to cardiac resynchronization therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial perfusion vasodilator or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography has been investigated as an off-label use of commercially available myocardial contrast agents or as an application for investigational agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. However, this modality is not yet FDA approved, techniques are not standardized, and use is not widespread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12182077\">",
"    <span class=\"h3\">",
"     Three-dimensional imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress echocardiography employing three-dimensional imaging has been investigated as a new method for evaluating wall motion and left ventricular systolic function. Compared to standard two-dimensional pharmacologic stress echocardiography, limited studies have shown similar success in acquiring images, sensitivity, and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the technique has not been studied amongst the general population of patients undergoing stress echocardiography and is not widely employed. With further development of three-dimensional echocardiography technology, this technique may become more useful in stress echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Strain imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue Doppler or speckle-tracking strain echocardiography can aid in detection of exercise or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    -induced ischemic regional LV systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. In addition, data suggest that detection of exercise-induced regional diastolic dysfunction by speckle-tracking may emerge as a method for detection of coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/36\">",
"     36",
"    </a>",
"    ]. One potential advantage of this technique is that postischemic regional diastolic abnormalities persist longer after exercise than systolic abnormalities. Small single center studies also suggest that this technique may be useful in the evaluation of myocardial viability in patients with ischemic left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7897?source=see_link\">",
"     \"Tissue Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As performed during any stress testing, monitoring of the patient&rsquo;s electrocardiogram, heart rate, blood pressure, and symptoms are required. The most common reason for test termination is completion of protocol or exercise-limiting symptoms, but other reasons for test termination include ST elevation, marked ST depression, sustained arrhythmias including bradycardia, atrial fibrillation, supraventricular tachycardia and ventricular tachycardia, severe hypertension (systolic blood pressure &gt;250 mmHg or diastolic blood pressure &gt;115 mmHg), or hypotensive response to exercise (",
"    <a class=\"graphic graphic_table graphicRef53266 \" href=\"mobipreview.htm?2/19/2365\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When performed carefully, the risks of exercise or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography testing are low. An evaluation of greater than 25,000 exercise stress echocardiography tests and greater than 35,000 dobutamine stress echocardiography tests revealed complication rates for life-threatening events of 0.015 percent for exercise testing as compared to 0.18 percent for dobutamine stress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Safety of dobutamine administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    is generally safe and well tolerated by patients, including elderly adults and those also receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, both cardiac and noncardiac side effects can occur. Serious complications, such as ventricular fibrillation or myocardial infarction, are rare, occurring in about one of every 2000 studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1,41\">",
"     1,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor arrhythmias, predominantly ventricular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atrial premature beats, occur in up to 30 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Atrial fibrillation and nonsustained ventricular tachyarrhythmias occur in one and three percent of studies, respectively; these arrhythmias are generally well tolerated, spontaneously resolve, and do not require treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Sustained ventricular tachycardia is rare, occurring in about 0.1 to 0.3 percent of studies; it was associated with left ventricular dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary artery disease in some but not all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although chest pain has been reported in up to 11 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    for stress testing, and is more likely in those with a history of angina or a recent myocardial infarction, in the experience of the authors it is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41\">",
"     41",
"    </a>",
"    ]. Serious complications from myocardial ischemia are also rare. In a review of over 4000 patients, there was only one case of nonfatal myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41\">",
"     41",
"    </a>",
"    ]. Symptomatic ischemia is effectively treated with discontinuation of dobutamine and sublingual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous beta-blocker.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    can also induce left ventricular mid-cavity and outflow tract obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The frequency of this phenomenon was illustrated by a prospective series of 237 patients referred for dobutamine stress echocardiography who did not have mid-cavity or outflow tract obstruction at rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/46\">",
"     46",
"    </a>",
"    ]. Mid-cavity and outflow tract obstruction were induced by dobutamine in 23 and 12 percent, respectively. Dobutamine-induced outflow tract obstruction was a significant predictor of future chest pain (52 versus 30 percent) and of syncope or near syncope (21 percent versus 9 percent). In comparison, the development of mid-cavity obstruction was not predictive of future cardiac events.",
"   </p>",
"   <p>",
"    There are a number of minor noncardiac side effects including nausea, anxiety, headache, tremor, and urinary urgency, which can lead to test termination in approximately 3 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef77326 \" href=\"mobipreview.htm?8/47/8957\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41\">",
"     41",
"    </a>",
"    ]. However, unlike adenosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    can be safely given to patients with reactive airways disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12181970\">",
"    <span class=\"h2\">",
"     Contrast agent safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA has issued a boxed warning for echocardiography contrast agents so patients must be screened for conditions that would preclude contrast administration, ie, hypersensitivity to the agents; known right to left, bidirectional, or transient right to left shunts; or egg allergy if using the agent Optison. High-risk patients including those with unstable cardiopulmonary syndromes must be monitored for at least 30 minutes after receiving contrast.",
"   </p>",
"   <p>",
"    A multicenter retrospective analysis of over 40,000 patients found that rates of death and myocardial infarction were not significantly different between patients receiving contrast and those not receiving contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients with pulmonary hypertension have been thought to have higher risk of receiving contrast agents, but an evaluation of over 25,000 patients showed that right ventricular systolic pressure had no impact on predisposition to adverse outcomes after receiving contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to both exercise and pharmacologic stress echocardiography are the same as those for standard exercise ECG testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=see_link&amp;anchor=H6#H6\">",
"     \"Performance of exercise ECG testing\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some have considered abdominal aortic aneurysm to be a contraindication to exercise testing or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography. However, there is evidence that such stress testing can be performed in this population with relative safety. In a review of 262 patients with an aneurysm diameter &gt;4 cm (average 5.5 cm), one patient (0.4 percent) with a 6.1 cm aneurysm had a contained rupture 12 hours after exercise, which was successfully repaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/49\">",
"     49",
"    </a>",
"    ]. In a report from the Mayo Clinic of 98 patients with an abdominal aortic aneurysm &ge;4 cm in diameter, there were no cases of aneurysm rupture or hemodynamic instability with dobutamine stress echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41048/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29359500\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two major types of stress echocardiography, exercise (treadmill or bicycle) stress echocardiography and pharmacologic (predominantly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) stress echocardiography, are used primarily to detect the presence (or absence) of ischemia secondary to obstructive coronary artery disease and to assess overall ventricular systolic function. In addition, Doppler echocardiographic imaging performed during or after exercise stress allows for evaluation of valvular function, pulmonary artery pressure, and left ventricular diastolic function. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several specific indications for stress echocardiography including (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Risk stratification for patients with known or suspected coronary artery disease",
"     </li>",
"     <li>",
"      Dyspnea of possible cardiac origin",
"     </li>",
"     <li>",
"      Pulmonary hypertension",
"     </li>",
"     <li>",
"      Valvular heart disease, including mitral stenosis, mitral regurgitation, and aortic stenosis",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The baseline (resting) echocardiogram obtained prior to stress should include a screening assessment of ventricular function, chamber sizes, wall thicknesses, aortic root diameter, and gross valvular structure and function, unless these have already been recently evaluated. Baseline and stress images are acquired in a variety of standard echocardiographic windows, including apical and parasternal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Imaging technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When performed carefully, the risks of exercise or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography testing are very low, with life-threatening complication rates of approximately 0.015 percent for exercise testing and 0.18 percent for dobutamine stress testing. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/1\">",
"      Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/2\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/3\">",
"      American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011; 57:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/4\">",
"      Ryan T, Feigenbaum H. Exercise echocardiography. Am J Cardiol 1992; 69:82H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/5\">",
"      Ryan T, Segar DS, Sawada SG, et al. Detection of coronary artery disease with upright bicycle exercise echocardiography. J Am Soc Echocardiogr 1993; 6:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/6\">",
"      Hecht HS, DeBord L, Sotomayor N, et al. Supine bicycle stress echocardiography: peak exercise imaging is superior to postexercise imaging. J Am Soc Echocardiogr 1993; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/7\">",
"      Hecht HS, DeBord L, Shaw R, et al. Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease. J Am Coll Cardiol 1993; 21:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/8\">",
"      Hecht HS, DeBord L, Shaw R, et al. Supine bicycle stress echocardiography versus tomographic thallium-201 exercise imaging for the detection of coronary artery disease. J Am Soc Echocardiogr 1993; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/9\">",
"      Hecht HS, DeBord L, Shaw R, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/10\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/11\">",
"      Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/12\">",
"      Kamaran M, Teague SM, Finkelhor RS, et al. Prognostic value of dobutamine stress echocardiography in patients referred because of suspected coronary artery disease. Am J Cardiol 1995; 76:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/13\">",
"      Elhendy A, Trocino G, Salustri A, et al. Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. Am Heart J 1996; 131:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/14\">",
"      La Canna G, Alfieri O, Giubbini R, et al. Echocardiography during infusion of dobutamine for identification of reversibly dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol 1994; 23:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/15\">",
"      Afridi I, Grayburn PA, Panza JA, et al. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J Am Coll Cardiol 1998; 32:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/16\">",
"      Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 1999; 33:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/17\">",
"      San Rom&aacute;n JA, Vilacosta I, Roll&aacute;n MJ, et al. Right ventricular asynergy during dobutamine-atropine echocardiography. J Am Coll Cardiol 1997; 30:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/18\">",
"      O'Sullivan CA, Duncan A, Daly C, et al. Dobutamine stress-induced ischemic right ventricular dysfunction and its relation to cardiac output in patients with three-vessel coronary artery disease with angina-like symptoms. Am J Cardiol 2005; 96:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/19\">",
"      Dolan MS, Riad K, El-Shafei A, et al. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. Am Heart J 2001; 142:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/20\">",
"      Vlassak I, Rubin DN, Odabashian JA, et al. Contrast and harmonic imaging improves accuracy and efficiency of novice readers for dobutamine stress echocardiography. Echocardiography 2002; 19:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/21\">",
"      Rainbird AJ, Mulvagh SL, Oh JK, et al. Contrast dobutamine stress echocardiography: clinical practice assessment in 300 consecutive patients. J Am Soc Echocardiogr 2001; 14:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/22\">",
"      Thanigaraj S, Nease RF Jr, Schechtman KB, et al. Use of contrast for image enhancement during stress echocardiography is cost-effective and reduces additional diagnostic testing. Am J Cardiol 2001; 87:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/23\">",
"      Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr 2008; 21:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/24\">",
"      Bernier M, Abdelmoneim SS, Moir S, et al. Pretest score for predicting microbubble contrast agent use in stress echocardiography: a method to increase efficiency in the echo laboratory. Cardiol Res Pract 2009; 2009:308486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/25\">",
"      Himelman RB, Stulbarg M, Kircher B, et al. Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation 1989; 79:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/26\">",
"      Rocchi G, Bertini M, Biffi M, et al. Exercise stress echocardiography is superior to rest echocardiography in predicting left ventricular reverse remodelling and functional improvement after cardiac resynchronization therapy. Eur Heart J 2009; 30:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/27\">",
"      Parsai C, Baltabaeva A, Anderson L, et al. Low-dose dobutamine stress echo to quantify the degree of remodelling after cardiac resynchronization therapy. Eur Heart J 2009; 30:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/28\">",
"      Moonen M, O'Connor K, Magne J, et al. Stress echocardiography for selecting potential responders to cardiac resynchronisation therapy. Heart 2010; 96:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/29\">",
"      Tsutsui JM, Elhendy A, Xie F, et al. Safety of dobutamine stress real-time myocardial contrast echocardiography. J Am Coll Cardiol 2005; 45:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/30\">",
"      Leistad E, Ohmori K, Peterson TA, et al. Quantitative assessment of myocardial perfusion during graded coronary artery stenoses by intravenous myocardial contrast echocardiography. J Am Coll Cardiol 2001; 37:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/31\">",
"      Jeetley P, Burden L, Greaves K, Senior R. Prognostic value of myocardial contrast echocardiography in patients presenting to hospital with acute chest pain and negative troponin. Am J Cardiol 2007; 99:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/32\">",
"      Sawada SG, Thomaides A. Three-dimensional stress echocardiography: the promise and limitations of volumetric imaging. Curr Opin Cardiol 2009; 24:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/33\">",
"      Voigt JU, Exner B, Schmiedehausen K, et al. Strain-rate imaging during dobutamine stress echocardiography provides objective evidence of inducible ischemia. Circulation 2003; 107:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/34\">",
"      Hanekom L, Cho GY, Leano R, et al. Comparison of two-dimensional speckle and tissue Doppler strain measurement during dobutamine stress echocardiography: an angiographic correlation. Eur Heart J 2007; 28:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/35\">",
"      Abraham TP, Dimaano VL, Liang HY. Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation 2007; 116:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/36\">",
"      Ishii K, Imai M, Suyama T, et al. Exercise-induced post-ischemic left ventricular delayed relaxation or diastolic stunning: is it a reliable marker in detecting coronary artery disease? J Am Coll Cardiol 2009; 53:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/37\">",
"      Becker M, Lenzen A, Ocklenburg C, et al. Myocardial deformation imaging based on ultrasonic pixel tracking to identify reversible myocardial dysfunction. J Am Coll Cardiol 2008; 51:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/38\">",
"      Bansal M, Jeffriess L, Leano R, et al. Assessment of myocardial viability at dobutamine echocardiography by deformation analysis using tissue velocity and speckle-tracking. JACC Cardiovasc Imaging 2010; 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/39\">",
"      Hoffmann R, Stempel K, K&uuml;hl H, et al. Integrated analysis of cardiac tissue structure and function for improved identification of reversible myocardial dysfunction. Coron Artery Dis 2009; 20:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/40\">",
"      Varga A, Garcia MA, Picano E, International Stress Echo Complication Registry. Safety of stress echocardiography (from the International Stress Echo Complication Registry). Am J Cardiol 2006; 98:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/41\">",
"      Mathias W Jr, Arruda A, Santos FC, et al. Safety of dobutamine-atropine stress echocardiography: A prospective experience of 4,033 consecutive studies. J Am Soc Echocardiogr 1999; 12:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/42\">",
"      Sheldon SH, Askew JW 3rd, Klarich KW, et al. Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes. J Am Soc Echocardiogr 2011; 24:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/43\">",
"      Karabinos I, Kranidis A, Papadopoulos A, Katritsis D. Prevalence and potential mechanisms of sustained ventricular arrhythmias during dobutamine stress echocardiography: a literature review. J Am Soc Echocardiogr 2008; 21:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/44\">",
"      Pellikka PA, Oh JK, Bailey KR, et al. Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation. Circulation 1992; 86:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/45\">",
"      Secknus MA, Niedermaier ON, Lauer MS, Marwick TH. Diagnostic and prognostic implications of left ventricular cavity obliteration response to dobutamine echocardiography. Am J Cardiol 1998; 81:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/46\">",
"      Dawn B, Paliwal VS, Raza ST, et al. Left ventricular outflow tract obstruction provoked during dobutamine stress echocardiography predicts future chest pain, syncope, and near syncope. Am Heart J 2005; 149:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/47\">",
"      Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. J Am Coll Cardiol 2009; 53:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/48\">",
"      Abdelmoneim SS, Bernier M, Scott CG, et al. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study. Circ Cardiovasc Imaging 2010; 3:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/49\">",
"      Best PJ, Tajik AJ, Gibbons RJ, Pellikka PA. The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms. Ann Intern Med 1998; 129:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41048/abstract/50\">",
"      Pellikka PA, Roger VL, Oh JK, et al. Safety of performing dobutamine stress echocardiography in patients with abdominal aortic aneurysm &gt; or = 4 cm in diameter. Am J Cardiol 1996; 77:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5324 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41048=[""].join("\n");
var outline_f40_5_41048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29359500\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMAGING TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Two-dimensional stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interpretation of two-dimensional images",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Use of contrast agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Doppler stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evolving technologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12182096\">",
"      - Evaluation for resynchronization therapy by stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12182077\">",
"      - Three-dimensional imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Strain imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Safety of dobutamine administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12181970\">",
"      Contrast agent safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29359500\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5324|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/21/1360\" title=\"figure 1\">",
"      LV wall motion analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/55/26487\" title=\"figure 2\">",
"      LV segmentation I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/25/21904\" title=\"figure 3\">",
"      Culprit lesion wall motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5324|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/19/2365\" title=\"table 2\">",
"      ACC AHA indication stopping ETT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/47/8957\" title=\"table 3\">",
"      Side effect pharm stress agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35047?source=related_link\">",
"      Low gradient aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35319?source=related_link\">",
"      Protocols for stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14167?source=related_link\">",
"      Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/5/10330?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_5_41049="Genetic abnormalities in hematologic and lymphoid malignancies";
var content_f40_5_41049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic abnormalities in hematologic and lymphoid malignancies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Iris Schrijver, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     James L Zehnder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Athena M Cherry, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41049/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/5/41049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human malignancies can be caused by a variety of mechanisms, including the inactivation of tumor suppressor genes, activation of oncogenes, and general genomic instability. The vast majority of human hematologic neoplasms are caused by the clonal expansion of a single cell that has acquired a somatic mutation in one allele of an otherwise normal gene (proto-oncogene) governing cellular maturation and division. This mutated gene, now called an oncogene, stimulates inappropriate cellular proliferation, leading to the development of cancer.",
"   </p>",
"   <p>",
"    Whereas multiple, random cytogenetic abnormalities are a characteristic finding in advanced malignancies, tumor-specific chromosomal translocations contribute directly to malignant transformation. Such translocations, and other genetic abnormalities, have been described for a large number of hematopoietic and lymphoid malignancies, including the acute and chronic lymphoid and myeloid leukemias, other myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma (plasma cell myeloma), and malignant lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A classic example is the Philadelphia chromosome (Ph), the first cytogenetic abnormality identified in a human malignancy, which is present in over 90 percent of individuals with chronic myeloid leukemia (CML). Initially described in 1960 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/3\">",
"     3",
"    </a>",
"    ], this small chromosome originates from the reciprocal translocation t(9;22)(q34;q11.2), which forms a transcriptionally active fusion gene between the BCR gene on chromosome 22 and the ABL1 locus on chromosome 9 (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ). The chimeric protein that is encoded by the newly created BCR-ABL1 gene on the Ph chromosome is involved in leukemogenesis through its interference with normal cell cycle events, such as signal transduction and the regulation of apoptosis and cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18167?source=see_link\">",
"     \"Chromosomal translocations, deletions, and inversions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BCR-ABL1 translocation is a diagnostic hallmark of CML and the only distinct chromosome abnormality seen in the chronic phase of this disorder. In addition, its presence is an important indicator of residual disease or relapse after treatment. Sensitive molecular genetic and cytogenetic methods to detect this translocation are now available for initial diagnosis and quantitative monitoring of disease status in patients with CML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link&amp;anchor=H8#H8\">",
"     \"Molecular genetics of chronic myeloid leukemia\", section on 'Detecting the Philadelphia chromosome or its products'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because BCR-ABL1 is the most common and best studied tumor-specific translocation in the hematopoietic malignancies, we shall use this fusion gene as a model for the ability of cytogenetic and molecular genetic diagnostic tools to help us understand the pathophysiology, diagnosis, treatment, prognosis, and monitoring of disease activity in the various hematologic malignancies. Methods for molecular and cytogenetic diagnosis are summarized separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHRONIC MYELOID LEUKEMIA AS A MODEL SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of chronic myeloid leukemia (CML) is approximately 1 to 2 cases per 100,000. It is slightly more common in males than in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/5\">",
"     5",
"    </a>",
"    ] and accounts for 15 to 20 percent of all leukemias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/4\">",
"     4",
"    </a>",
"    ]. Because it is a disorder arising from a mutational event in a somatic cell, chromosomes in all tissues are normal except in affected cells within the hematopoietic system. In one study for example, the Philadelphia chromosome was found in cells from all hematopoietic lineages with the exception of mature T-lymphocytes, supporting the hypothesis that CML results from a single aberrant chromosomal event occurring in a pluripotent hematopoietic stem cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H6496975#H6496975\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'Cell of origin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     BCR and ABL1 genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Philadelphia chromosome is a derivative chromosome 22 [der(22)] created by a reciprocal translocation between the region containing the BCR gene on the long arm of chromosome 22 (22q) and the segment that contains the ABL1 gene on the long arm of chromosome 9 (9q) (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     ABL1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large ABL1 gene spans approximately 225 kilobases (kb). After the intervening sequences (introns) are spliced out, the gene can be expressed as a 6.0 or 7.0 kb messenger RNA (mRNA). This range in sizes is due to the alternative splicing of exons 2 through 11 to either exon 1a or, less commonly, to exon 1b, which is larger, as shown in panel A (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). The resulting protein is a tyrosine kinase with a molecular weight of 145 kilodalton (kD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H11#H11\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'c-ABL1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     BCR gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BCR gene on chromosome 22 encompasses 134 kb and encodes 23 exons. It was named after the 5.8 kb major",
"    <strong>",
"     B",
"    </strong>",
"    reakpoint",
"    <strong>",
"     C",
"    </strong>",
"    luster",
"    <strong>",
"     R",
"    </strong>",
"    egion that includes 5 exons (b1 through b5) located in a central area of the gene, as shown in panel B (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). The BCR mRNAs are 4.5 or 6.7 kb in size; both encode a 160 kD protein with",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H10#H10\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     BCR/ABL1 fusion gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;In t(9;22), the BCR gene on chromosome 22 fuses with the ABL1 proto-oncogene from chromosome 9 in a head-to-tail manner, forming a novel 8.5 kb mRNA, as shown in panel C (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). This mRNA comprises about half of the BCR exons at the centromeric 5' end, and ABL1 exons 2 to 11 towards the 3' end [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/7\">",
"     7",
"    </a>",
"    ]. The breakpoints in the major breakpoint cluster region (M-bcr) are located either between exons b2 and b3 (exons 13 and 14 of the BCR gene), or between exons b3 and b4 (BCR exons 14 and 15). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H12#H12\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR-ABL1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indication of exons within the breakpoint cluster region (ie, exons b1 through b5), rather than a numbering according to their position within the BCR gene as a whole (ie, exons 12 through 16), dates back to the time when the BCR gene was not yet fully characterized and remains popular in the literature. To avoid confusion with other reports, we will adhere to this original BCR breakpoint indication. Whereas ABL1 breakpoints can occur 5' to exon 1b, as well as in introns 1, 2, or 3, the great majority of patients demonstrate a chimeric transcript in which the BCR segment is spliced to exon a2 of the ABL1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/9\">",
"     9",
"    </a>",
"    ]. Therefore, the RNA transcripts in most patients consist of ABL1 a2, spliced to BCR exons b2 or b3, denoted as b2a2 or b3a2, as shown in panel C (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). In some patients with a confirmed b3a2 junction, coexpression of transcripts b3a2 and b2a2 can be detected, due to alternative splicing in which exon b3 is selectively spliced out. The encoded fusion protein, commonly described as",
"    <span class=\"nowrap\">",
"     p210BCR/ABL1,",
"    </span>",
"    because of its molecular weight of 210 kDa, possesses the oncogenic dysregulated kinase activity.",
"   </p>",
"   <p>",
"    Virtually all patients with CML exhibit the b2a2 or the b3a2 junction, generated by a breakpoint within M-bcr. In addition to M-bcr, however, two other breakpoint cluster regions have been identified. The minor breakpoint cluster region, m-bcr, is located upstream of M-bcr (ie, towards the centromeric, or 5' end) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/10\">",
"     10",
"    </a>",
"    ], and the micro breakpoint cluster region (&micro;-bcr) is located downstream of M-bcr, towards the telomeric, or 3' end, as shown in panel B (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The m-bcr is rarely affected in individuals with CML, but serves as a breakpoint for two thirds of patients with ALL. The e1a2 fusion arises after alternative exons 1 and 2 are selectively spliced out, as shown in panel B (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). The resulting protein is only 190 kD, smaller than the product of the M-bcr [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/12\">",
"     12",
"    </a>",
"    ]. Only in rare cases is a breakpoint in the &micro;-bcr identified. The junction between BCR exon 19 and ABL1 exon 2 leads to a 230 kD protein product, as shown in panels A, B, and C (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ), which has been described in CML and, more frequently, in patients with chronic neutrophilic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chronic neutrophilic leukemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     ABL1/BCR fusion gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;In reciprocal translocations, two non-homologous chromosomes exchange parts. As a consequence of the BCR-ABL1 translocation, chromosome 9 should exhibit fusion with the telomeric chromosome piece that was separated from chromosome 22 (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ). This rarely reported reciprocal product [der(9)] was demonstrated to be present in approximately 60 percent of patients with CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/14\">",
"     14",
"    </a>",
"    ]. In the BCR-ABL1 hybrid product, the ABL1 breakpoint is observed at exon a2 because the splicing machinery selectively removes the exons upstream. When the ABL1-BCR fusion gene undergoes transcription, however, the ABL1 breakpoint commonly occurs upstream of exon 1b, between exons 1b and 1a, or downstream of exon 1a, as shown in panel A (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). This leads to a greater variety of fusion transcripts, consisting of a small portion of the ABL1 gene and a larger portion of the BCR gene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link&amp;anchor=H6#H6\">",
"     \"Molecular genetics of chronic myeloid leukemia\", section on 'Reciprocal translocation product'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The observation of one (or occasionally more, when alternative splicing occurs within one individual) of the four 1b-BCR messages (1be2,1bb3,1bb4 and 1be20) in the majority of CML cases, has been ascribed to the sizable intron between ABL1 exons 1b and 1a, which is likely to contain the preponderance of ABL1 breakpoints. The newly formed junctions are in-frame and encode a message that could be translated into a functional protein sequence and expressed by the cell. The significance of the ABL1-BCR fusion protein, however, is still unclear. A major role in leukemogenesis is improbable, because it is not expressed in 40 percent of Ph positive CML patients. However, there are some reports of decreased survival rates in CML patients who have a deletion of ABL1 on the derivative chromosome 9, as well as deletion of the proximal region, including the argininosuccinate synthase gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Further prospective studies are necessary to clarify this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69720132\">",
"    <span class=\"h2\">",
"     Infrequent breakpoints in BCR and ABL1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 10 percent of CML clones have breakpoints outside the M-bcr. Apart from the e1a2 or e1a3 junctions in m-bcr (described above), and the infrequent e19a2 transcript in &micro;-bcr, there are a few rare outliers. These include fusion transcripts b2a3, e1a3, e19a3, e20a3 and e6a2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/17\">",
"     17",
"    </a>",
"    ]. Occasionally, translocation breakpoints can occur within coding exons, as exemplified in two patients with partial e8a2 and partial b2a2 fusions, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69720139\">",
"    <span class=\"h3\">",
"     Clinical implications of various breakpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considering the variety of BCR and ABL1 breakpoints as well as RNA transcripts in CML, the question arises whether these molecular differences induce phenotypic variation in disease course and survival. Whereas some early reports suggested such correlations, other studies refute the early results. In one large-scale prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/19\">",
"     19",
"    </a>",
"    ], no prognostic association between the genomic M-bcr breakpoint site or RNA message, and duration of the chronic phase or survival, was detected. The only possible correlation that was detected in a small number of patients whose WBC count was lower than",
"    <span class=\"nowrap\">",
"     100,000/&micro;L,",
"    </span>",
"    was one between platelet count and the b3a2 transcript.",
"   </p>",
"   <p>",
"    In contrast to the lack of genotype-phenotype variation within M-bcr CML, distinct clinical features, resembling both CML and CMML, are exhibited by patients who express",
"    <span class=\"nowrap\">",
"     p190BCR/ABL1",
"    </span>",
"    due to a breakpoint in m-bcr. There is an increase in peripheral immature granulocytes, considerable monocytosis, and a variable degree of basophilia. These features are consistent with a myeloproliferative disorder that includes expansion of the monocytic lineage, which is not characteristic of CML with",
"    <span class=\"nowrap\">",
"     p210BCR/ABL1.",
"    </span>",
"    This observation is supported by the fact that all cases of m-bcr AML fell into the French-American-British (FAB) classification M4 or M5a, which are subgroups with myelomonocytic (M4) or monocytic (M5) proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults with ALL who express either",
"    <span class=\"nowrap\">",
"     p210BCR/ABL1",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     p190BCR/ABL1",
"    </span>",
"    are phenotypically very similar, but in children there may be a distinction. Childhood ALL due to a breakpoint in M-bcr is uncommon, but, when present, tends to be associated with hyperleukocytic ALL (",
"    <a class=\"graphic graphic_table graphicRef66337 \" href=\"mobipreview.htm?3/50/3884\">",
"     table 1",
"    </a>",
"    ). Firm conclusions, however, cannot be drawn, due to the small number of patients studied and the possibility that their malignancy may represent lymphoid blast crisis after an undiagnosed prior chronic phase of CML. However, in all types of ALL, the presence of Ph confers a poor prognosis.",
"   </p>",
"   <p>",
"    The largest fusion protein described for the BCR-ABL1 translocation has a molecular weight of 230 kD and is most often associated with chronic neutrophilic leukemia (CNL). This rare disorder is closely related to CML, but in most instances, the disease course is more prolonged and symptoms are less severe. Compared with classic CML, the WBC count is lower and anemia is less pronounced. Moreover, the percentage of peripheral immature granulocytes is low and the spleen is only mildly enlarged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/13\">",
"     13",
"    </a>",
"    ]. Only 2 of 10 CNL patients reported to date have progressed to the acute leukemic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/21\">",
"     21",
"    </a>",
"    ]. A subset of patients has significant thrombocytosis, but the etiology of this finding is, as yet, unknown. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Chronic neutrophilic leukemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to ALL, CML patients in whom no BCR-ABL1 fusion product can be detected have a lower survival rate than individuals with the translocation. The patients who lack BCR-ABL1 are of a higher age, have lower WBC counts, higher frequency of thrombocytopenia, less prominent basophilia, and an increasing leukemic burden, even though progression to overt blast crisis is less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69719826\">",
"    <span class=\"h2\">",
"     Detection of Ph and BCR-ABL1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely applied diagnostic method for CML is karyotyping of metaphase chromosomes by cytogenetic studies (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ). The Ph chromosome is identified in approximately 90 percent of new patients with CML, and the progression to a more aggressive leukemic stage can be detected or confirmed by the emergence of additional structural or numerical chromosome abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DNA-based polymerase chain reaction (PCR) analysis and Southern blotting can determine individual breakpoints precisely, but are less suitable for routine translocation detection, due to the broad distribution of possible translocation breakpoints and the prohibitive length of some introns. The intron-less mRNA transcript, on the other hand, is an excellent molecular template and reverse transcriptase polymerase chain reaction (RT-PCR) will detect a BCR-ABL1 fusion in an additional one-half of the patients who are Ph negative by chromosome banding techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/23\">",
"     23",
"    </a>",
"    ]. This highly sensitive method can detect the mutation in a single cell in a background of at least 10",
"    <sup>",
"     6",
"    </sup>",
"    unaffected cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69719942\">",
"    <span class=\"h2\">",
"     Ph chromosome negative CML",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 5 percent of clinically diagnosed patients with CML, no Ph is detected by standard cytogenetics. With the advent of molecular genetic studies such as FISH, Southern blotting and PCR, however, a subgroup of patients with microscopically undetectable translocations has been uncovered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/24\">",
"     24",
"    </a>",
"    ]. Some of these cases proved to be caused by complex gene rearrangements, involving one or more chromosomes in addition to 9 and 22 (",
"    <a class=\"graphic graphic_figure graphicRef74102 \" href=\"mobipreview.htm?31/1/31761\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other instances, the translocation of material from the ABL1 gene to chromosome 22 is non-reciprocal and more difficult to detect. A contributing factor to apparent Ph and BCR-ABL1 negativity may be the choice of probes used in the detection assay. Most studies that have investigated BCR-ABL1 negative CML have selected probes that would be unable to detect breakpoints in regions outside the M-bcr.",
"   </p>",
"   <p>",
"    A small subset of patients may indeed lack the BCR-ABL1 hybrid gene. The majority of these cases have an atypical disease course with less frequent progression to blast crisis, and may need to be categorized under different diagnoses, such as chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia, or \"atypical CML\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Chronic neutrophilic leukemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H64021188#H64021188\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS/MPN syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69719770\">",
"    <span class=\"h2\">",
"     Monitoring of residual disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of CML was revolutionized by the introduction of the ABL1 kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    and its congeners. It is now standard to assess response to therapy by quantitative real time PCR; a 3 log reduction from baseline is considered a good response. Occasionally a patient will develop resistance to imatinib, usually due to acquired mutations in the ABL1 kinase domain. This important subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Monitoring response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     THE PH CHROMOSOME IN MALIGNANCIES OTHER THAN CML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas Ph is a recognized hallmark of CML, it is by no means exclusive to this disorder, and has been seen in acute lymphoblastic leukemia, acute myeloid leukemia, and other hematologic malignancies (",
"    <a class=\"graphic graphic_table graphicRef66337 \" href=\"mobipreview.htm?3/50/3884\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ph translocation is the most commonly detected chromosomal abnormality in ALL and has been identified in 5 percent of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/27\">",
"     27",
"    </a>",
"    ] and in almost one third of adults with this malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/28\">",
"     28",
"    </a>",
"    ]. In those instances in which pediatric ALL is Ph-positive, 85 percent carry a breakpoint in m-bcr and express",
"    <span class=\"nowrap\">",
"     p190BCR/ABL1.",
"    </span>",
"    The remaining 15 percent have a breakpoint in M-bcr (",
"    <a class=\"graphic graphic_table graphicRef66337 \" href=\"mobipreview.htm?3/50/3884\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In Ph positive adults with ALL, the reverse transcription polymerase chain reaction technique (RT-PCR) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    ) has discerned the e1a2 transcript with",
"    <span class=\"nowrap\">",
"     p190BCR/ABL1",
"    </span>",
"    expression in 50 to 77 percent of cases, and b3a2 or b2a2 transcripts with",
"    <span class=\"nowrap\">",
"     p210BCR/ABL1",
"    </span>",
"    expression in 23 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link&amp;anchor=H6#H6\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\", section on '9;22 translocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ph chromosome is identified in only a small minority of patients with acute myeloid leukemia (AML) (",
"    <a class=\"graphic graphic_table graphicRef66337 \" href=\"mobipreview.htm?3/50/3884\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/29\">",
"     29",
"    </a>",
"    ], and has been the subject of debate. Initially, it was thought that Ph-positive AML was equivalent to CML in blast crisis, but several distinguishing features support the view that they are, in fact, separate entities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary chromosomal abnormalities are common in the acute (blastic) phase of CML, while these are not observed in newly diagnosed AML.",
"     </li>",
"     <li>",
"      All cells that originated from the initially mutated stem cell in CML carry the Ph translocation. The acute leukemias, on the other hand, generally exhibit both BCR-ABL1 positive and negative cells at the time of diagnosis.",
"     </li>",
"     <li>",
"      The Philadelphia chromosome commonly persists when CML is in remission, while cytogenetic normalization is a frequent finding in acute leukemia in remission.",
"     </li>",
"     <li>",
"      The frequency and type of additional chromosome aberrations can provide clues as to which diagnosis is most likely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/25\">",
"       25",
"      </a>",
"      ]. In AML, breakpoints have been reported in M-bcr and m-bcr [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/29,30\">",
"       29,30",
"      </a>",
"      ], and putative AML has also been associated with a breakpoint in &micro;-bcr [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic neutrophilic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with chronic neutrophilic leukemia have no detectable cytogenetic abnormalities, but when chromosomal studies demonstrate the presence of Ph, a breakpoint in the 3' &micro;-bcr (e19a2, p230) is typical. This disorder is characterized by a more benign course than classical CML, although the number of patients with a &micro;-bcr t(9;22) is small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Chronic neutrophilic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other hematologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, BCR-ABL1 has been described in essential thrombocytosis, myelodysplastic syndrome, multiple myeloma (plasma cell myeloma), and malignant lymphoma. The mere presence of a BCR-ABL1 rearrangement in these disorders, however, does not prove that it is the primary cause. Since the number of chromosomal abnormalities tends to increase during the course of these chronic disorders, the appearance of the Ph chromosome may be interpreted as a secondary abnormality.",
"   </p>",
"   <p>",
"    An alternative explanation is that the patient has been incorrectly diagnosed. As an example, the Polycythemia Vera Study Group collected 6 patients who were originally diagnosed as having essential thrombocythemia, but were Philadelphia chromosome positive. Five of the six patients subsequently developed a clinical course typical of CML, including termination in blast crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ACUTE MYELOID LEUKEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 45 percent of patients with acute myeloid leukemia (AML), two (or more) structural or numerical cytogenetic anomalies occur, either as primary or secondary events. Exceptions exist for acute promyelocytic leukemia (FAB subtype M3), in which t(15;17) can be demonstrated in approximately 80 percent of cases and for FAB subgroup M4E, in which most patients exhibit t(16;16) or inv(16). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link\">",
"     \"Molecular biology of acute promyelocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identification of cytogenetic anomalies affects initial diagnosis in ambiguous cases and becomes highly relevant for the determination of prognosis, appropriate clinical management, detection of relapse, and the elucidation of AML pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H2#H2\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=see_link&amp;anchor=H6273191#H6273191\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerical abnormalities that consist of the gain of a chromosome in the clonal cell population (hyperdiploidy) include trisomy 4, 8, 21 and 22. Of these, chromosome 8 is most frequently encountered, without preference for a particular FAB subtype. The most specific hyperdiploidy is trisomy 22 which often occurs in conjunction with inv(16)-positive subgroup FAB M4E. In contrast, hypodiploidy, and monosomy 7 or 7q- in particular, is most often identified in FAB subtypes M4 and M6. The table summarizes the most common cytogenetic changes in each FAB subgroup, most of which are structural rather than numerical (",
"    <a class=\"graphic graphic_table graphicRef71750 \" href=\"mobipreview.htm?28/39/29308\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many genes that are involved in AML chromosomal translocations and inversions have now been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/35\">",
"     35",
"    </a>",
"    ]. Perhaps the best known example is the MLL (mixed lineage leukemia) gene on chromosome 11 band q23. This gene is implicated in AML (5 percent), ALL (10 percent), infant leukemias (up to 80 percent), and leukemias of mixed",
"    <span class=\"nowrap\">",
"     AML/ALL",
"    </span>",
"    lineage. An exceptional feature of MLL translocations is that fusions with a wide variety of chromosomes have been reported. The most frequently identified reciprocal translocations are t(6;11), t(11;19) and t(9;11). The latter carries a more favorable prognosis than other 11q23 translocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MYELODYSPLASTIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the etiology of the myelodysplastic syndromes (MDS) and their genotype-phenotype correlations are complex and, as yet, largely unknown. Whereas some patients may have a benign disease course without a terminal leukemic phase, the cytogenetic abnormalities that are often present in these disorders underscore their clonal nature. Chromosomal changes accumulate in the more malignant phases of MDS, which may reflect a general genomic instability. Not surprisingly, the vast majority of cytogenetic changes in MDS are also seen in AML, supporting the view that these disorders represent a continuum rather than strictly separate entities. Nevertheless, there are several distinct characteristics of MDS, including an occurrence at a higher age than most forms of AML, multi-lineage dysplasia, and the presence of unbalanced translocations.",
"   </p>",
"   <p>",
"    The International Prognostic Scoring System (IPSS), which has been devised for MDS, is based in part on the presence of chromosomal abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H5#H5\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on 'Cytogenetics as a predictor of prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An unfavorable prognosis is associated with partial deletion of chromosome 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/37\">",
"     37",
"    </a>",
"    ]. Ten percent of",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    patients have a monosomy 7 or a deletion of 7q; patients with these karyotypes are prone to much faster progression to acute leukemia. Deletions of the long arms of chromosomes 5, 9, 11, 13, and 20, a deletion of the short arm of chromosome 12, inversions of chromosome 3, as well as translocations t(6;9), t(8;21) and t(9;11) are also fairly common.",
"   </p>",
"   <p>",
"    Thirty percent of MDS patients exhibit the 5q- syndrome, characterized by a region of variable chromosomal loss which always includes the region between 5q22 and 5q31. This critical region contains several growth factor genes, loss of which could disturb hematopoietic cell differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H256821606#H256821606\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on '5q- syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is a malignancy of plasma cells, the most differentiated of the B-lymphocytes. As these cells have limited mitotic activity, cytogenetic abnormalities are not as easily detected as in other hematopoietic neoplasias. Sensitive techniques such as FISH, however, enable the detection of one or more karyotypic anomalies in approximately 80 percent of myeloma patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Cytogenetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A chromosome defect is identified in nearly one-half of patients with monoclonal gammopathy of undetermined significance (MGUS), while multiple anomalies are much more prevalent in MM. The cytogenetic deviations in MM are mostly non-specific, a fact that has hampered prognostic correlations. Patients with abnormal karyotypes are hyperdiploid in 65 percent and carry hypodiploidy in 20 percent. Partial chromosome gains or losses, as well as other structural abnormalities are present in 15 percent of patients. In this group, a 14q+ marker is most frequently encountered. A relatively poor prognosis is associated with partial or complete deletion of chromosome 13, or anomalies of the long arm of chromosome 11. When these abnormalities co-exist, the average event-free survival after autologous bone-marrow transplant is reduced by one-half, compared with patients with a single defect in chromosome 11 or 13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some B cell acute lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    (B-ALL) are associated with recurrent genetic abnormalities. The translocation t(9;22), which creates the Philadelphia chromosome (Ph), is present in approximately 25 percent of adults and 5 percent of children affected by B-ALL. In the presence of Ph, the likelihood of a favorable outcome in both children and adults is significantly reduced compared with other cytogenetic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/34\">",
"     34",
"    </a>",
"    ]. In children, the t(12;21)(p13;q22) or ETV6-RUNX1 (formerly TEL-AML1) rearrangement occurs in approximately 25 percent of cases of B-ALL and is associated with a favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerical chromosome changes are present in a minority of patients with B-ALL. Hypodiploidy carries a relatively poor prognosis, but is a feature in less than 8 percent of children with ALL. An increased chromosome number is seen in approximately 40 percent of children with ALL and is considered a favorable prognostic feature, except in the presence of i(17q). Hyperdiploidy is often accompanied by structural rearrangements, but recurrent translocations are rare and the isolation of specific breakpoint genes remains impractical. Hence, in order to monitor residual disease, interphase FISH is by and large more useful than RT-PCR, provided that the appropriate probes are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exceptions to this rule include translocations t(1;19)(q23;p13) and its variant t(17;19)(q21;p13). At least one quarter of childhood pre-B cell ALL and 5 percent of all pediatric ALLs are associated with this rearrangement. The hybrid transcript of the PBX and E2A genes or the HLF and E2A genes, respectively, can easily be detected by RT-PCR. Similarly, RT-PCR can be applied for the detection of the MLL-AF4 fusion hybrid in t(4;11), which is present in 70 percent of affected children younger than 12 months. The presence of this, or other MLL fusions, predicts a poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2769079\">",
"    <span class=\"h1\">",
"     T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the present World Health Organization (WHO) classification, T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) are represented in a single category of T lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma.",
"    </span>",
"    It is not yet clear, however, whether T-ALL and T-LBL are indeed reflective of the same conditions or should be regarded as two separate entities. A meta-analysis has demonstrated that translocations involving chromosome region 9q34 are significantly more common in T-LBL than in T-ALL. In this chromosomal region, the SET, ABL1, NUP214, and NOTCH1 are known to play a role in leukemogenesis, but further studies are required to determine how these translocations contribute to disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/43\">",
"     43",
"    </a>",
"    ]. Fifty to 70 percent of T-ALL are associated with cytogenetic abnormalities, most commonly involving the TCR gene loci (7p14-15, TCRG locus; 7q35, TCRB locus; 14q11, TCRA and TCRD) with a number of partner genes. Partners include TAL1 (1P32) in up to 30 percent of childhood T-ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/44\">",
"     44",
"    </a>",
"    ], HOX11 (10q24), HOX11L2 (5q35), LMO1, LMO2, NOTCH1, and LYL1 (19p13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/45\">",
"     45",
"    </a>",
"    ]. Deletions of CDKN2A occur in more than 30 percent of patients and lead to cell cycle activation. Mutations resulting in activation of NOTCH1 occur in 50 percent of T-ALL and result in a proliferative signal via the MYC gene. Activating mutations in FLT3 and NRAS have also been described, as have gene duplications of MYB and the formation of fusion genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CHRONIC B CELL AND T CELL LEUKEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on morphological, immunophenotypic, and genetic evidence, most patients with chronic lymphocytic leukemias (eg, chronic lymphocytic leukemia, B cell prolymphocytic leukemia, hairy cell leukemia) demonstrate clonal abnormalities in mature B cells. The subset of chronic T cell leukemias includes T cell prolymphocytic leukemia and large granular lymphocyte leukemia.",
"   </p>",
"   <p>",
"    As these chronic leukemias are primarily disorders of mature cells which may not readily divide in culture, cytogenetic abnormalities are not readily detectable by metaphase analysis. However, molecular cytogenetic methods such as FISH have greatly improved sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/46\">",
"     46",
"    </a>",
"    ]. The cytogenetic abnormalities occurring with the highest incidence in chronic lymphocytic leukemia are trisomy 12 in approximately 20 percent of cases and rearrangements of chromosome 13 and 14. In half of the patients with trisomy 12, the cells exhibit atypical morphology, as opposed to fewer than 10 percent of patients without this aneuploidy. Survival, however, seems to be negatively influenced only in patients with low stage disease. Loss of heterozygosity in tumor suppressor genes, such as RB1 in chromosome band 13q14, BRCA2 in 13q12 and P53 in 17p12 are frequent findings in accelerated CLL, but are highly non-specific. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interphase fluorescence in situ hybridization (FISH) has shown abnormalities in at least 80 percent of CLL patients. In one study, 13q deletion was the most commonly observed anomaly (55 percent of patients), while 11q deletion and trisomy 12 were observed in approximately 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/47\">",
"     47",
"    </a>",
"    ]. There were at least three categories of risk, as defined by the FISH anomalies &ndash; a poor risk group that consisted of 17p or p53 deletions, an intermediate risk group that consisted of trisomy 12q or a normal karyotype, and a good risk group that consisted of 13q deletions.",
"   </p>",
"   <p>",
"    T cell PLL is characterized by complex rearrangements, the most consistent of which are t(14;14)(q11;q32) or inv(14)(q11;q32). The T cell receptor (TCR) gene on 14q11 is thus merged with the TCL1 gene on 14q32, resulting in overexpression of the latter. Another frequent finding in T cell PLL is partial trisomy 8 with upregulation of the CMYC oncogene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10102?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite major advances in cytogenetics, the etiology of Hodgkin lymphoma remains elusive. Many patients with Hodgkin lymphoma appear to have normal karyotypes, although some tumors exhibit complex chromosomal changes and gross aneuploidy. Hyperploidy and deletions of chromosomes 1p, 4q, 6q or 7q are regularly encountered in Hodgkin lymphoma. A specific rearrangement that could lead to the identification of affected genes, however, has not yet been found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in non-Hodgkin lymphoma, several disease-specific chromosomal changes have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/49\">",
"     49",
"    </a>",
"    ]. These are detailed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Burkitt lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The translocations in Burkitt lymphoma are imprecise events, compared with the exact gene fusions present in CML and ALL. Burkitt lymphoma arises when the CMYC gene on chromosome 8, band q24 is juxtaposed to one of the immunoglobulin loci on chromosome 14 (the immunoglobulin heavy chain), chromosome 22 (the lambda light chain), or chromosome 2 (the kappa light chain). The translocation breakpoints are variable and occur in a very large region in and around the CMYC gene, but all lead to the aberrant overexpression of this otherwise tightly regulated gene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Translocations involving the c-MYC oncogene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The translocation t(14;18)(q32;q21), which is identified in approximately 80 percent of follicular B cell lymphomas and almost one third of diffuse large cell lymphomas, is often accompanied by additional chromosome aberrations. By this translocation, which is another example of an imprecise fusion, the BCL2 gene on chromosome 18q is juxtaposed to the constitutively expressed Ig heavy chain gene on chromosome 14q; BCL2 is upregulated as a consequence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Cytogenetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cyclin D1 gene is often overexpressed in mantle cell lymphoma, when t(11;14)(q13;q32), which is present in almost all cases of mantle cell lymphoma, places this gene adjacent to the immunoglobulin heavy chain gene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Genetic features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anaplastic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty to 40 percent of pediatric large cell lymphomas are anaplastic. The typical rearrangement in these instances is t(2;5)(p23;q35). This translocation is an occasional manifestation in adult primary systemic anaplastic large cell lymphomas as well, and confers a good prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41049/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69718091\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of human hematologic neoplasms are caused by the clonal expansion of a single cell that has acquired a somatic mutation in one allele of an otherwise normal gene (proto-oncogene) governing cellular maturation and division. This mutated gene, now called an oncogene, stimulates inappropriate cellular proliferation, leading to the development of cancer.",
"     </li>",
"     <li>",
"      Whereas multiple, random cytogenetic abnormalities are a characteristic finding in advanced malignancies, tumor-specific chromosomal translocations contribute directly to malignant transformation. Such translocations, and other genetic abnormalities, have been described for a large number of hematopoietic and lymphoid malignancies. The clonal myeloproliferative neoplasm chronic myeloid leukemia (CML) provides a model for such translocations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chronic myeloid leukemia as a model system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CML is derived from an abnormal pluripotent stem cell that has acquired the BCR-ABL1 fusion gene. This fusion gene is the product of a balanced translocation between chromosomes 9 and 22, denoted t(9;22) (q34.1;q11.21), which juxtaposes a 5&rsquo; segment of a breakpoint cluster region (BCR) at 22q11 and the 3&rsquo; segment of the ABL oncogene (ABL1) at 9q34, resulting in an abnormally small chromosome known as the Philadelphia (Ph) chromosome. As a consequence of the BCR-ABL1 translocation, chromosome 9 should also exhibit fusion with the telomeric chromosome piece that was separated from chromosome 22 (",
"      <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"       figure 1",
"      </a>",
"      ), reported as the reciprocal product der(9). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'BCR and ABL1 genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing for the Ph chromosome, the BCR-ABL1 fusion gene or the fusion mRNA gene product can be done by conventional cytogenetic analysis (karyotyping), fluorescence in situ hybridization (FISH) analysis, by reverse transcription polymerase chain reaction (RT-PCR), or by Southern blot. Karyotyping is widely applied for the diagnosis of CML while quantitative RT-PCR is frequently employed to assess response to therapy. (See",
"      <a class=\"local\" href=\"#H69719826\">",
"       'Detection of Ph and BCR-ABL1'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H69719770\">",
"       'Monitoring of residual disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whereas the Ph chromosome is a recognized hallmark of CML, it is by no means exclusive to this disorder, and has been seen in acute lymphoblastic leukemia, acute myeloid leukemia, and other hematologic malignancies. The mere presence of a BCR-ABL1 rearrangement in these disorders, however, does not prove that it is the primary cause. Since the number of chromosomal abnormalities tends to increase during the course of these chronic disorders, the appearance of the Ph chromosome may be interpreted as a secondary abnormality. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'The Ph chromosome in malignancies other than CML'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent genetic abnormalities are commonly found in other hematologic and lymphoid malignancies. In many of these disorders, assessment for genetic changes is a routine part of the diagnostic evaluation and the results of such tests often affect prognosis and treatment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/1\">",
"      Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/2\">",
"      Rowley JD. Chromosomal translocations: revisited yet again. Blood 2008; 112:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/3\">",
"      Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960; 132:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/4\">",
"      Warmuth M, Danhauser-Riedl S, Hallek M. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Ann Hematol 1999; 78:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/5\">",
"      Call TG, No&euml;l P, Habermann TM, et al. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1994; 69:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/6\">",
"      Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92:4758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/7\">",
"      Rowley JD. The Philadelphia chromosome translocation. A paradigm for understanding leukemia. Cancer 1990; 65:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/8\">",
"      Chissoe SL, Bodenteich A, Wang YF, et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/9\">",
"      Groffen J, Heisterkamp N. The chimeric BCR-ABL gene. Baillieres Clin Haematol 1997; 10:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/10\">",
"      Chen SJ, Chen Z, Hillion J, et al. Ph1-positive, bcr-negative acute leukemias: clustering of breakpoints on chromosome 22 in the 3' end of the BCR gene first intron. Blood 1989; 73:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/11\">",
"      Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/12\">",
"      Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol 1997; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/13\">",
"      Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/14\">",
"      Melo JV, Gordon DE, Cross NC, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/15\">",
"      Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/16\">",
"      Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/17\">",
"      Hochhaus A, Reiter A, Skladny H, et al. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 1996; 88:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/18\">",
"      How GF, Lim LC, Kulkarni S, et al. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. Br J Haematol 1999; 105:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/19\">",
"      Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/20\">",
"      Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/21\">",
"      How GF, Tan LT, Lim LC. Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction--is it truly a benign disease? Leukemia 1998; 12:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/22\">",
"      Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996; 100:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/23\">",
"      Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 1999; 93:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/24\">",
"      Reddy KS, Grove B. A Philadelphia-negative chronic myeloid leukemia with a BCR/ABL fusion gene on chromosome 9. Cancer Genet Cytogenet 1998; 107:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/25\">",
"      Yee K, Anglin P, Keating A. Molecular approaches to the detection and monitoring of chronic myeloid leukemia: theory and practice. Blood Rev 1999; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/26\">",
"      Kurzrock R, Kantarjian HM, Shtalrid M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood 1990; 75:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/27\">",
"      Suryanarayan K, Hunger SP, Kohler S, et al. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood 1991; 77:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/28\">",
"      Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/29\">",
"      Paietta E, Racevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998; 12:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/30\">",
"      Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991; 78:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/31\">",
"      Haskovec C, Ponzetto C, Pol&aacute;k J, et al. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 1998; 103:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/32\">",
"      Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol 1988; 27:77.",
"     </a>",
"    </li>",
"    <li>",
"     Heim S, Mitelman F. Acute myeloid leukemia. In: Cancer Cytogenetics, Wiley-Liss, New York 1995. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/34\">",
"      Martinez-Climent JA. Molecular cytogenetics of childhood hematological malignancies. Leukemia 1997; 11:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/35\">",
"      Martinez-Climent JA, Garc&iacute;a-Conde J. Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. J Pediatr Hematol Oncol 1999; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/36\">",
"      Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev Genet 1998; 32:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/37\">",
"      Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/38\">",
"      Dewald GW, Wright PI. Chromosome abnormalities in the myeloproliferative disorders. Semin Oncol 1995; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/39\">",
"      Tabernero D, San Miguel JF, Garcia-Sanz M, et al. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 1996; 149:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/40\">",
"      Feinman R, Sawyer J, Hardin J, Tricot G. Cytogenetics and molecular genetics in multiple myeloma. Hematol Oncol Clin North Am 1997; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/41\">",
"      Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86:4263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/42\">",
"      Lanza C, Volpe G, Basso G, et al. Outcome and lineage involvement in t(12;21) childhood acute lymphoblastic leukaemia. Br J Haematol 1997; 97:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/43\">",
"      Sekimizu M, Sunami S, Nakazawa A, et al. Chromosome abnormalities in advanced stage T-cell lymphoblastic lymphoma of children and adolescents: a report from Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) and review of the literature. Br J Haematol 2011; 154:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/44\">",
"      Cazzaniga G, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood ALL. Best Pract Res Clin Haematol 2002; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/45\">",
"      Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/46\">",
"      Brito-Babapulle V, Garcia-Marco J, Maljaie SH, et al. The impact of molecular cytogenetics on chronic lymphoid leukaemia. Acta Haematol 1997; 98:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/47\">",
"      D&ouml;hner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/48\">",
"      Atkin NB. Cytogenetics of Hodgkin's disease. Cytogenet Cell Genet 1998; 80:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/49\">",
"      Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000; 96:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41049/abstract/50\">",
"      Heerema NA. Chromosomes in lymphomas and solid tumors. Cancer Invest 1998; 16:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4500 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41049=[""].join("\n");
var outline_f40_5_41049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H69718091\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHRONIC MYELOID LEUKEMIA AS A MODEL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BCR and ABL1 genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - ABL1 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - BCR gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - BCR/ABL1 fusion gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - ABL1/BCR fusion gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69720132\">",
"      Infrequent breakpoints in BCR and ABL1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69720139\">",
"      - Clinical implications of various breakpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69719826\">",
"      Detection of Ph and BCR-ABL1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69719942\">",
"      Ph chromosome negative CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69719770\">",
"      Monitoring of residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      THE PH CHROMOSOME IN MALIGNANCIES OTHER THAN CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic neutrophilic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ACUTE MYELOID LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MYELODYSPLASTIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2769079\">",
"      T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CHRONIC B CELL AND T CELL LEUKEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anaplastic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69718091\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4500|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/20/16719\" title=\"figure 1\">",
"      The Philadelphia chromosome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/41/9886\" title=\"figure 2\">",
"      ABL1 and BCR genes in CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/1/31761\" title=\"figure 3\">",
"      Complex rearrangement in CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4500|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/50/3884\" title=\"table 1\">",
"      BCR breakpoints in leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/39/29308\" title=\"table 2\">",
"      Cytogenetics in AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=related_link\">",
"      Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_5_41050="Hemophagocytic lymphohistiocytosis";
var content_f40_5_41050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemophagocytic lymphohistiocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41050/contributors\">",
"     Kenneth L McClain, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41050/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/5/41050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/5/41050/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/5/41050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H526310\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophagocytic lymphohistiocytosis (HLH) is also known as autosomal recessive familial hemophagocytic lymphohistiocytosis (FHL), familial erythrophagocytic lymphohistiocytosis (FEL), and viral-associated hemophagocytic syndrome (VAHS). This aggressive and potentially life-threatening disease most often affects infants from birth to 18 months of age, but cases in older children and adults have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of the term \"primary HLH\" to denote the presence of an underlying genetic disorder and \"secondary HLH\" to denote presence of the HLH phenomenon occurring secondary to another condition (eg, viral illness, autoimmune disease, lymphoma) has caused a great deal of confusion among clinicians. This reflects the fact that in patients with inherited mutations predisposing to HLH, clinical symptoms are often triggered by viral infections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In pediatric patients, the same gene mutations can be present in both situations and there is no specific test with the ability to quickly define these two categories.",
"     </li>",
"     <li>",
"      In adult patients, genetic mutations are much less common, suggesting that most represent \"secondary HLH.\" (See",
"      <a class=\"local\" href=\"#H12959587\">",
"       'Underlying genetic defects'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With few exceptions, the clinical presentation and outcome are the same for both. A review has been written to help clinicians understand the many signs and symptoms of HLH besides the eight diagnostic criteria that can help with diagnosing this illness as well as the subtleties of its treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLH and a similar disorder, the macrophage activation syndrome (MAS), which occurs primarily in patients with juvenile idiopathic arthritis or systemic lupus erythematosus, will be discussed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Sweden, the incidence of HLH is estimated to be 1.2 children per million per year, or 1 in 50,000 live births, with a male-to-female ratio close to 1:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/7\">",
"     7",
"    </a>",
"    ]. Many children with HLH are probably not diagnosed, so its incidence may be higher, as suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The difficulty in making the diagnosis is illustrated by the results of one series in which the diagnosis of HLH was made antemortem in only 11 of 32 patients with HLH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Initial signs and symptoms of HLH are the same as, or mimic, common infections, fever of unknown origin, hepatitis, multiple organ failure syndrome, encephalitis, and even child abuse (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Initial presentation'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of HLH cases from the largest pediatric hospitals in Texas revealed an incidence of 1 in 100,000 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSOCIATED ILLNESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLH may be familial, associated with a number of different infections, autoimmune disorders, or coincident with a number of malignancies. These are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the infections associated with HLH are Epstein-Barr virus, cytomegalovirus, parvovirus, herpes simplex, varicella-zoster, measles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/9\">",
"     9",
"    </a>",
"    ], as well as human herpes virus-8 and HIV infection, alone or in combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. HLH may occur shortly after the initiation of highly active antiretroviral therapy (HAART) in treatment of HIV-AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/13\">",
"     13",
"    </a>",
"    ]. HLH may coincide with various bacterial infections (Brucella, gram negative bacteria, tuberculosis), parasites (Leishmaniasis), and fungal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The functional status of certain EBV nuclear antigen (EBNA) genes may dictate whether this virus causes typical infectious mononucleosis or HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/15\">",
"     15",
"    </a>",
"    ]. The EBV LMP1 gene interferes with the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) defective in the X-linked lymphoproliferative disease (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Other conditions'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/16\">",
"     16",
"    </a>",
"    ]. It was hypothesized that the excessive T cell activation and enhanced Th1 cytokine secretion from EBV infection is a common pathway for both diseases. In some EBV+ HLH patients the virus infects CD8+ T cells and causes a clonal expansion of large T cells with down-regulation of CD5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/17\">",
"     17",
"    </a>",
"    ]. As the patient improves with therapy and the ferritin decreases, this population of T cells also decreases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Hemophagocytic lymphohistiocytosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10473?source=see_link&amp;anchor=H5#H5\">",
"     \"Infectious causes of neutropenia\", section on 'Brucellosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HLH may complicate H1N1 infections and be a factor in patients&rsquo; deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of adult patients with HLH and a variety of autoimmune diseases including lupus erythematosus, rheumatoid arthritis, Still's disease, polyarteritis nodosa, mixed connective tissue disease, pulmonary sarcoidosis, systemic sclerosis, and Sjogren's syndrome has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Some of these patients developed HLH following infection with a microorganism while others developed HLH with the onset of their primary disease. (See",
"    <a class=\"local\" href=\"#H19714867\">",
"     'HLH in adults'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Macrophage activation syndrome'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Drug-induced hypersensitivity syndrome, also called drug rash with eosinophilia and systemic symptoms (DRESS), which shares many of the characteristics of adult-onset Still's disease, has also been associated with the presence of hemophagocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug eruptions\", section on 'Hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLH has been found in patients with immune deficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/24\">",
"     24",
"    </a>",
"    ], including the X-linked lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], common variable immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/26\">",
"     26",
"    </a>",
"    ], and in renal or liver transplant recipients in whom it may accompany an EBV-lymphoproliferative syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], Kawasaki disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/30\">",
"     30",
"    </a>",
"    ], Griscelli syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/31\">",
"     31",
"    </a>",
"    ], and Hermansky-Pudlak syndrome type II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=see_link&amp;anchor=H8#H8\">",
"     \"Syndromic immunodeficiencies\", section on 'Griscelli syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33384?source=see_link\">",
"     \"X-linked lymphoproliferative disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HLH is also found coincident with leukemias and lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/33-39\">",
"     33-39",
"    </a>",
"    ], and probably is the etiology of the \"accelerated phase\" of the Chediak Higashi syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35126?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link&amp;anchor=H8#H8\">",
"     \"Primary disorders of phagocytic function: An overview\", section on 'Chediak-Higashi syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytophagic histiocytic panniculitis, a rare systemic disorder consisting of lobular panniculitis, fever, hepatosplenomegaly, liver failure, infiltration with cytophagic histiocytes, and an association with subcutaneous panniculitis-like T cell lymphoma, may also have features of secondary HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35126?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link&amp;anchor=H2492480#H2492480\">",
"     \"Panniculitis: Recognition and diagnosis\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased incidence of the hemophagocytic syndrome has been described after the use of umbilical cord blood for hematopoietic cell transplantation in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/43\">",
"     43",
"    </a>",
"    ]. The mechanism is unclear but may be due to a reduced dose of CD34+ cells along with increased reactivity of donor immune cells, resulting in hemophagocytosis and loss of the stem cell graft.",
"   </p>",
"   <p>",
"    In occasional cases, a clearly-defined underlying disorder (eg, immune deficiency state, malignancy) cannot be found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Familial HLH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 25 percent of all HLH cases are familial and frequently associated with parental consanguinity. Similar laboratory and clinical findings are present in most patients with HLH; accordingly, no laboratory test or mode of presentation provides a rapid means to distinguish between familial or sporadic cases. However, evaluation for mutations in perforin, Munc 13-4, syntaxin, and related genes may provide definitive evidence for HLH and allow for genetic screening or prenatal diagnosis of potentially affected family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19714867\">",
"    <span class=\"h2\">",
"     HLH in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been no epidemiologic study of HLH in adults; accordingly, the incidence is unknown. The seminal paper on viral-associated hemophagocytic syndrome reported on a number of adults who were infected with herpes or other viruses while immunosuppressed post renal transplant or because of systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/45\">",
"     45",
"    </a>",
"    ]. Fourteen of their patients (ages 3 to 61, median 27 years) developed HLH two weeks to 88 months after starting immunosuppression with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and steroids. Interestingly, all of the renal transplant patients",
"    <span class=\"nowrap\">",
"     (13/14)",
"    </span>",
"    had splenectomies and received anti-thymocyte globulin. Treatments included reduction of immunosuppression and giving supportive care, including broad spectrum antibiotics. Four of the 14 patients died. Other reported studies in adults include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of 23 adults with HLH who were identified by an increase in marrow histiocytes has been presented [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/3\">",
"       3",
"      </a>",
"      ]. Fourteen of the 23 patients had a herpes virus infection. Seven had rheumatologic diseases and were treated with steroids or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . Seven had some type of malignancy including lymphoma, leukemia, teratoma, or breast cancer. One patient was presumed to have X-linked lymphoproliferative disease (XLP), one had hepatitis of unknown origin, and two had AIDS. The overall mortality in this series was 20 percent. The authors also reviewed 50 cases published prior to their article in 1988. Of the 40 patients in the literature with documented infection 42 percent died, while the mortality in the 10 patients without documented infection was 100 percent.",
"     </li>",
"     <li>",
"      A study of 34 adult HLH patients (22 males) was reported from Japan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/46\">",
"       46",
"      </a>",
"      ]. Fourteen survived (median age 30 years) and 20 died (median age 54 years). Hematologic malignancies or viral illnesses were present in 14 (seven died of HLH) and no underlying illness in 20 (13 died of HLH). Twenty-four patients were treated with a variety of chemotherapy regimens, including CHOP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ) (eight patients); or CHOP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      or etoposide alone (seven patients); prednisolone (six patients); and methyl prednisolone pulse therapy (three patients). Only one of the patients receiving chemotherapy survived. None received etoposide plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      according to the HLH-94 regimen. Prognostic factors associated with death were age over 30 years, anemia, and thrombocytopenia on admission with worsening of those laboratory values as well as increase in total bilirubin, DIC, and elevated ferritin.",
"     </li>",
"     <li>",
"      Another series of 26 HLH cases associated with systemic lupus erythematosus (14), rheumatoid arthritis (two), adult onset systemic Still&rsquo;s disease (four), and a variety of other connective tissue diseases was reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/47\">",
"       47",
"      </a>",
"      ]. Isolated HLH occurred in two cases, but was associated with infections in 15 and the rheumatologic disease in nine cases. At the time of HLH onset, patients were receiving a variety of treatments including corticosteroids alone, and steroids plus oral chemotherapy. Nineteen patients received only steroids for treatment of their HLH, three received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and steroids, two were treated with immunoglobulins. Ten patients died: four attributed to HLH, three from multiple organ failure, and three from infections. Mortality was associated with absence of lymphadenopathy, thrombocytopenia, and immunosuppressive therapies given at the time of HLH. As with the prior report, none of these patients was treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The use of CHOP chemotherapy for adult patients with HLH has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/48\">",
"       48",
"      </a>",
"      ]. Patients whose primary disease was lymphoma had a better outcome with CHOP therapy (three out of seven alive) than those with a primary EBV infection (two out of five alive) or no underlying disease (one out of five alive).",
"     </li>",
"     <li>",
"      Another study reported 18 cases of secondary HLH, with patients treated primarily with corticosteroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and some with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , IVIG,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or other chemotherapy with 72 percent mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over the past two decades, a variety of patients have been reported who presented with HLH in association with peripheral T cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/33\">",
"     33",
"    </a>",
"    ], natural killer cell leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/34,50\">",
"     34,50",
"    </a>",
"    ], EBV in T cell lymphoma mimicking malignant histiocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/51\">",
"     51",
"    </a>",
"    ], B cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/35\">",
"     35",
"    </a>",
"    ] and a variety of other lymphomas, including a presenting symptom of anaplastic large cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with rheumatologic disease can develop the Macrophage Activation Syndrome (MAS) similar to that described in children, with the same caveats regarding relative diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In a cohort of patients with adult-onset Still disease, 15 percent developed MAS as characterized by: fever, pancytopenia, liver failure, coagulopathy, and neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/56\">",
"     56",
"    </a>",
"    ]. All patients had elevated serum ferritin and low levels of glycosylated ferritin. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Macrophage activation syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the literature would suggest that most adults with HLH have some underlying autoimmune or malignant disease, some do present with the bewildering array of findings similar to those seen in children. Often they present as patients with an infection of unknown origin, hepatitis, or cytopenias. It behooves the clinician to consider HLH when such a patient is being evaluated with fever, cytopenias, elevated liver function tests, and coagulopathy. By checking serial ferritin levels, NK cell function and serum interleukin-2 receptor levels, the diagnosis of HLH may become apparent. As with children, it is neither necessary nor sufficient to demonstrate hemophagocytosis in bone marrow or lymph node biopsies in order to make this diagnosis, provided that other diagnostic criteria are present (",
"    <a class=\"graphic graphic_table graphicRef80721 \" href=\"mobipreview.htm?25/0/25612\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment of adult patients with HLH should follow the guidelines described below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12959587\">",
"    <span class=\"h3\">",
"     Underlying genetic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some adult patients with HLH are found to have mutations in the perforin gene, but for unknown reasons do not present in the first few years of life as do some children with the same mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/4,57\">",
"     4,57",
"    </a>",
"    ]. Two siblings presented in their early 20s: one with prominent CNS findings and the other with a T cell lymphoblastic lymphoma. They had a common perforin mutation associated with HLH (Trp374Stop as well as Ala91Val).",
"   </p>",
"   <p>",
"    This issue was reviewed in a study of 175 adult patients referred for genetic testing due to a suspected diagnosis of HLH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/58\">",
"     58",
"    </a>",
"    ]. Twenty-five of these adults (14 percent), with an age at the time of disease onset ranging from 18 to 75 years, possessed mutations or sequence variants in PRF1, MUNC 13-4, or STXBP2. These were either missense or splice-site changes representing hypomorphic mutations (ie, partial defects) that played a contributing role in the development of late-onset HLH when patients were challenged with a viral infection or other environmental challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathway implicated in most instances of HLH, the lack of perforin-dependent cytotoxicity, is an essential function of natural killer (NK) and cytotoxic T lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. These cells normally store perforin and granzyme proteins in specialized secretory lysosomes that are secreted when they encounter a virally-infected or tumor-derived target cell, leading to apoptosis. When perforin-mediated cytotoxicity is diminished or absent as a result of the disruption of a gene or genes mediating this pathway, severe immune dysregulation results, usually following an infectious or immune stimulus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H26#H26\">",
"     \"The adaptive cellular immune response\", section on 'T cell cytotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=see_link&amp;anchor=H8#H8\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\", section on 'Mechanisms of killing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This overall process is postulated to progress, as in the case of viral infection, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a normal immune response, foreign viral antigen is presented by antigen-presenting cells (APCs, eg, macrophages, dendritic cells, B lymphocytes) to CD4+ and CD8+ T cells.",
"     </li>",
"     <li>",
"      In response, T cells are activated and proliferate and differentiate, during which time they produce a variety of cytokines (eg, interferon-gamma), which activate APCs to further promote antigen presentation. (See",
"      <a class=\"local\" href=\"#H19079095\">",
"       'Cytokine levels'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      This mutually stimulatory phase is normally controlled by an inhibitory feedback loop when the NK and CD8+ T cells acquire cytotoxic function and begin to kill virally infected cells, including macrophages and other APCs, via perforin-dependent mechanisms.",
"     </li>",
"     <li>",
"      In HLH, the failure of these perforin-dependent mechanisms allows for spiraling immune activation, with abnormal and excessive production of T cell-derived cytokines (eg, &ldquo;cytokine storm&rdquo;), leading to uncontrolled accumulation of activated T-lymphocytes and activated histiocytes (macrophages) in various tissues, resulting in hemophagocytosis and organ damage. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pathologic findings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of the immune system in HLH patients have shown that immunoglobulin levels are normal, despite the relatively low numbers of B cells. Other lymphocyte subset numbers (including NK-cells) are normal except in EBV-associated cases, which have a high number of",
"    <span class=\"nowrap\">",
"     CD3+/HLA",
"    </span>",
"    DR+ T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/62\">",
"     62",
"    </a>",
"    ]. A sophisticated analysis of T cells from one HLH patient revealed an unusual expanded subpopulation of",
"    <span class=\"nowrap\">",
"     \"effector/memory",
"    </span>",
"    phenotype\" T cells with lower than expected CD5 expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/63\">",
"     63",
"    </a>",
"    ]. A measure of episomal DNA fragments from T cell receptors proved these cells had been proliferating for a relatively long time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19079095\">",
"    <span class=\"h2\">",
"     Cytokine levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central pathophysiologic abnormality in HLH is cytokine dysfunction, resulting in uncontrolled accumulation of activated T-lymphocytes and activated histiocytes (macrophages) in many organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Key cytokines found at extremely high levels in the plasma of patients with HLH include interferon gamma (Ifn-&gamma;), interleukins (IL)-6, (IL)-10, IL-12, and soluble IL-2 receptor (CD25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Elevated IL-16 levels may be important for a TH1-type response that recruits macrophages and other cells pertinent to HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/69\">",
"     69",
"    </a>",
"    ]. In a study of adults with secondary HLH, markedly elevated levels of IL-18 and its binding protein were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/70\">",
"     70",
"    </a>",
"    ]. While IL-18 supposedly stimulates macrophages and NK cells, it may accelerate NK cell apoptosis in patients with HLH, causing the marked reduction in NK cell numbers.",
"   </p>",
"   <p>",
"    The relative amounts of Ifn-&gamma;, IL-10, and IL-6 are particularly useful for distinguishing HLH from sepsis and viral infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/71\">",
"     71",
"    </a>",
"    ]. In one study, the levels of these three cytokines were compared among controls, patients with sepsis, and those with HLH, with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Median Ifn-&gamma; levels in controls, sepsis, and HLH were 5.2, 6.4, and 1088",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Median IL-10 levels were 6.7, 40.5, and 624",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Median IL-6 levels were 5.5, 325, and 51",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When using the criteria of Ifn-&gamma; &gt;75 and IL-10 &gt;60, the sensitivity and specificity for the diagnosis of HLH were 98.9 and 93.0 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Natural killer cell and cytotoxic T cell activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups have found depressed or absent natural killer (NK)-cell and cytotoxic T cell activity in HLH patients and family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/73-76\">",
"     73-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to cytotoxicity assays, flow cytometry-based assays that quantify perforin, SLAM-associated protein (SAP), and X-linked inhibitor of apoptosis (XIAP) can identify the specific cellular defects in those with FHL2, XLP1, and XLP2 abnormalities, respectively. The other genes associated with HLH encode proteins implicated in the transport and exocytosis of lytic granules by cytotoxic lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Genetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Different types of NK deficiency have been identified in HLH by varying the culture conditions with the addition of IL-2 or employing longer incubation times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. The authors suggested that multiple levels of cell signaling were likely to be involved in the defective NK function in HLH patients. Ultimately, through the use of these data one may be able to define which patients will absolutely need hematopoietic cell transplantation [HCT] in order to cure their HLH. This may be especially true for those with type 3 NK cell deficiency, in whom NK cellular toxicity is totally absent, and neither stimulation with PHA nor recombinant human IL-2 nor prolongation of incubation times restores the deficient cytolytic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, HLH patients less than two years of age, or with persistently low NK cell activity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overt central nervous system disease, had a poor survival unless they received HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, none of the 36 patients with type 3 NK cell deficiency attained a remission lasting more than one year without receiving HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Perforin expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of perforin expression, as well as the cytotoxic function of T and NK cells in HLH has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/75,83\">",
"     75,83",
"    </a>",
"    ]. Four-color flow cytometric analysis has proven to be a rapid technique for quantitating perforin expression in different cell types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/84\">",
"     84",
"    </a>",
"    ]. Four of seven patients with HLH lacked intracellular perforin in all cytotoxic cell types; three had normal numbers of perforin-positive cells. On the other hand, patients with EBV-associated HLH had depressed NK cell function and numbers, but increased relative numbers of CD8+ T cells expressing perforin. This methodology may prove critical in the diagnosis of patients and family members at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A murine model of HLH with perforin-deficient mice has been developed in which the CD8(+) T cells, not the NK cells, were shown to be critical in causing HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/61\">",
"     61",
"    </a>",
"    ]. The mice developed HLH only after a viral infection (lymphocytic choriomeningitis virus), which was associated with increased antigen presentation to CD8(+) T cells and increased production of interferon-gamma. The animals could be cured using antibodies to interferon gamma, suggesting a potential therapeutic intervention for patients with HLH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides perforin, defects in other proteins of the cytolytic pathway have been associated with defective T cell control and HLH. The MUNC13-4 protein is important for packaging of the cytolytic granzymes and HLH patients with mutations of this gene have been designated FHL3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/75,87\">",
"     75,87",
"    </a>",
"    ]. Patients with the Griscelli syndrome often develop HLH and have been shown to lack a protein rab27a that controls secretion of lytic granules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/88\">",
"     88",
"    </a>",
"    ]. Munc 13-4 must link with rab27a to allow fusion of secretory granules with the plasma membrane. The mechanism(s) of T cell dysregulation remain unclear.",
"   </p>",
"   <p>",
"    Another piece of the puzzle may be explained by a defect in patients with Chediak-Higashi syndrome, who also have a high frequency of HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/40,89\">",
"     40,89",
"    </a>",
"    ]. In these patients the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) does not move from secretory lysosomes to the cell membrane. While there have been little prior data on alterations of the cytolytic enzymes (granzymes) carried into the pores, mutations in three alleles of granzyme, called the QPY haplotype, have been detected in patients with EBV-HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another cellular defect in HLH relates to defective apoptosis, as less spontaneous activation of caspase-3-like enzymes was found in activated lymphocytes of some HLH patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/91\">",
"     91",
"    </a>",
"    ]. This could be a possible mechanism for accumulation of the large numbers of lymphocytes seen in lymph nodes, spleen, liver, or bone marrow in patients with HLH. A review of the links between perforin expression, lymphocyte cytotoxicity, and triggering of apoptosis has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genes localized to chromosomes 6, 9, 10, and 17 have been reported to be associated with HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/76,87,93-95\">",
"     76,87,93-95",
"    </a>",
"    ]. Linkage analysis has identified the 9q21.3-22 region (FHL1) with HLH, but a specific gene has not yet been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/93\">",
"     93",
"    </a>",
"    ]. The perforin gene (PRF1 gene, FHL2) localized at 10q21-22 is especially interesting because it plays a central role in NK cell activity (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defects in a number of genes have been linked to familial HLH (FHL). All mutations recognized to date affect granule-dependent cytotoxicity, interfering with the function of both natural killer cells and cytotoxic lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/96\">",
"     96",
"    </a>",
"    ]. Upon contact between the effector killer cell and the target cell, an immunological synapse is formed and cytolytic granules traffic to the contact site, dock and fuse with the plasma membrane, and release their contents. All known defects in HLH as listed below seem to be involved in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FHL1 &mdash; gene not yet described, located in chromosome 9q21.3-22 region",
"     </li>",
"     <li>",
"      FHL2 &mdash; Perforin (PRF1, located at 10q21-22)",
"     </li>",
"     <li>",
"      FHL3 &mdash; Munc 13-4 (UNC13D, located at 17q25)",
"     </li>",
"     <li>",
"      FHL4 &mdash; Syntaxin 11 (STX11, located at 6q24)",
"     </li>",
"     <li>",
"      FHL5 &mdash; Munc 18-2 (STXBP2, located at 19p13)",
"     </li>",
"     <li>",
"      RAB27A &mdash; Griscelli syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      LYST &mdash; Chediak-Higashi syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multi-ethnic cohort of 76 patients with familial HLH originating from 65 unrelated families, biallelic mutations in PRF1, UNC13D, and STX11 were found in 18, 10, and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/97\">",
"     97",
"    </a>",
"    ]. No molecular diagnosis was established in 45 percent of those analyzed for all three of these genes. Patients carrying PRF1 mutations had a significantly higher risk of early disease onset (ie, &lt;6 months) than those carrying STX11 mutations (adjusted odds ratio 8.2; 95% CI 1.2-56). In a study of 63 unrelated patients with FHL of different geographic origins, mutations in perforin, MUNC 13-4, or syntaxin were seen in 80 percent of those of Turkish origin, but in only 30 percent of those of German origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Perforin (PRF1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutational and linkage analysis of 34 European families of HLH patients indicated that perforin mutations and the resulting perforin deficiency accounted for 20 to 40 percent of familial cases, and the FHL 1 locus on chromosome 9 for approximately 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/94\">",
"     94",
"    </a>",
"    ]. Since perforin gene polymorphisms are found in normal individuals, the link between mutations and polymorphisms in this gene and HLH is complex, although defects in perforin synthesis are clearly associated with the disease.",
"   </p>",
"   <p>",
"    In one study of North American HLH patients (not viral-associated), 58 percent had perforin (PRF1) mutations, 13 of which were novel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/99\">",
"     99",
"    </a>",
"    ]. Absent or decreased perforin protein levels correlated with mutations in the perforin gene. Patients with mutations who presented at later ages had residual perforin expression, but early-onset HLH patients usually had no perforin in their NK or CD8+ cells.",
"   </p>",
"   <p>",
"    Japanese patients had two mutations (1090-1091 delCT and 207 delC) that differed from those reported in European and North American series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/100\">",
"     100",
"    </a>",
"    ]. None of the EBV-HLH patients had a perforin gene mutation. Interestingly, founder gene effects were reported for Black patients in one series (50del T) and for patients from Western Japan in a second report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of 22 affected patients from 14 different families with perforin gene mutations revealed the following relationships between perforin mutation and disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/86\">",
"     86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the patients carrying perforin null mutations presented with HLH within the first three months of life. Those with missense mutations had a greater variability in disease onset (one to 144 months).",
"     </li>",
"     <li>",
"      Perforin deficiency and an absence of T cell activation were found in a totally asymptomatic one-month-old child of a family with two previously affected members, strongly suggesting that an external cause (eg, infection) is necessary in order to trigger disease activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An HLH patient with an inframe deletion of the perforin gene that resulted in perforin expression at the lower end of the normal range has been reported, showing that total lack of perforin is not necessary for disease expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional analysis of the perforin mutations by in vitro systems demonstrate reduced levels of perforin, perhaps from rapid degradation due to misfolding of the protein, loss-of-function mutations, or abnormal processing of the protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An in vitro system to test the proteins produced by missense perforin mutations has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/107\">",
"     107",
"    </a>",
"    ]. Class 1 mutations allowed lytic function and some protein detection, but variable cytotoxic function in carriers. Class 3 mutations had markedly lower perforin levels and cytotoxicity, while class 2 mutations were intermediate in their effects. The authors concluded that a protein dosage effect resulted from the perforin missense mutations.",
"   </p>",
"   <p>",
"    A Japanese group reported on the clinical effects of perforin or MUNC13-4 mutations in FHL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Patients with missense perforin gene mutations had a later disease onset (&ge;7 years of age) as opposed to those with nonsense mutations, who presented before the first year of life. The latter patients also had the highest serum ferritin and soluble IL-2 levels. Patients with MUNC 13-4 mutations all presented before 10 months of age. Another study evaluated the mutations of 175 HLH patients 18 years or older and found mis-sense and splice-site sequence variants (hypomorphic mutations) in 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/58\">",
"     58",
"    </a>",
"    ]. Twelve of these patients had the A91V-PRF1 genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Munc 13-4 (UNC13D)",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLH patients who express perforin, but have mutations in the hMunc13-4 family of genes on 17q25.1 have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/87\">",
"     87",
"    </a>",
"    ]. These genes are necessary for secretion of cytolytic granules and may, like perforin, have a role in T cell regulation. One study found two pathogenic, non-coding, deep intronic mutations in the",
"    <em>",
"     UNC13D",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/110\">",
"     110",
"    </a>",
"    ]. Both the point mutation in intron 1 and an inversion affecting the 3&rsquo; end of the transcript prevented Munc13-4 expression. These two genetic changes in familial HLH patients along with the known perforin, RB27a, could account for mutations in all Scandinavian FHL patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Syntaxin 11 (STX11)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another member of the",
"    <span class=\"nowrap\">",
"     endocytic/exocytic",
"    </span>",
"    pathway is the syntaxin 11 gene on chromosome 6 in which deletions have been found in a group of Kurdish families with several HLH cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/95\">",
"     95",
"    </a>",
"    ]. A study of the clinical associations of syntaxin 11 gene mutations in familial HLH patients has been reported in which all of the patients had normal perforin genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/111\">",
"     111",
"    </a>",
"    ]. While some patients had remissions of over one year without treatment, others with syntaxin gene mutations developed severe psychomotor retardation and two developed a myelodysplastic syndrome or acute myeloid leukemia. A study of 243 North American HLH patients referred for syntaxin testing revealed only three patients with mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/112\">",
"     112",
"    </a>",
"    ]. Two patients with nonsense mutations presented during infancy and one with a missense mutation presented at five years of age.",
"   </p>",
"   <p>",
"    NK cells from syntaxin-deficient subjects fail to degranulate when encountering susceptible target cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/113\">",
"     113",
"    </a>",
"    ]. IL-2 stimulation partially restores degranulation and cytotoxicity.",
"   </p>",
"   <p>",
"    A subset of FHL-5 patients have mutations in the STXBP2 (syntaxin binding protein 2), which is important for regulation of vesicle transport to the plasma membrane. Syntaxin 11 interacts with STXBP2 and is eliminated by missense mutations found in FHL-5 patients resulting in reduced NK and cytotoxic T cell activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Munc 18-2 (STXBP2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene encoding syntaxin-binding protein 2 (STXBP2) is mutated in a subset of patients with familial HLH, resulting in defective cytotoxic activity of NK cells, a disorder that has been initially designated as FLH5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/115\">",
"     115",
"    </a>",
"    ]. Initial data indicate that STXBP2 is required at a late step in the secretory pathway for the release of cytotoxic granules by binding syntaxin 11, another component of the intracellular membrane fusion pathway.",
"   </p>",
"   <p>",
"    In a study of 37 patients with mutations in STXBP2, approximately half were from Saudi Arabia, United Arab Emirates, or Turkey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. Besides the typical presenting signs and symptoms of HLH, approximately one-third of those with FLH-5 have",
"    <span class=\"nowrap\">",
"     colitis/diarrhea,",
"    </span>",
"    bleeding disorders, and hypogammaglobulinemia. Bleeding may occur in these patients from a failure of platelet alpha and delta granules to be secreted in response to thrombin. A sensorineural hearing deficit has also been described, the cause of which is uncertain.",
"   </p>",
"   <p>",
"    In the large cohort study of 37 patients, those with exon 15 splice site mutations developed clinical manifestations later than those with other mutations (median age 4.1 years versus two months) and showed less severe impairment of degranulation and cytotoxic function of NK cells and cytotoxic lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19715226\">",
"    <span class=\"h3\">",
"     XIAP (BIRC4)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten patients from eight families have been reported with mutations in the BIRC4 gene, which had been originally described as one of the causes of X-linked lymphoproliferative disease (ie, X-linked inhibitor of apoptosis, XIAP, XLP type 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/119\">",
"     119",
"    </a>",
"    ]. Nine of these 10 patients developed HLH and none had lymphoma. After further characterization of this disorder, it appears that XIAP deficiency is better classified as X-linked familial HLH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33384?source=see_link&amp;anchor=H1#H1\">",
"     \"X-linked lymphoproliferative disease\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19715234\">",
"    <span class=\"h3\">",
"     Cytotoxic T-lymphocyte-associated antigen 4 and HLH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forty-three Japanese children with infection-associated HLH were investigated for polymorphisms of the CTLA-4 gene, a negative regulator of T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/120\">",
"     120",
"    </a>",
"    ]. The frequency of the AT(&gt;)(7) allele was significantly higher in the patients with HLH than in the controls. Patients homozygous for the CTLA-4 AT(&gt;)(7) allele showed significantly higher serum levels of lactate dehydrogenase and soluble interleukin-2 receptor than patients with the other alleles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Associated genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLH has been associated with X-linked lymphoproliferative disease, type 1 (XLP1). In a study of 25 male patients with HLH, four had germline mutations in SH2D1A (also known as SAP and DSHP), the gene defective in XLP1 (",
"    <a class=\"graphic graphic_table graphicRef58918 \" href=\"mobipreview.htm?21/40/22155\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/25\">",
"     25",
"    </a>",
"    ]. Of the four affected individuals, two had family histories consistent with XLP1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HLH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33384?source=see_link&amp;anchor=H3#H3\">",
"     \"X-linked lymphoproliferative disease\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Japanese study of 32 EBV-associated HLH patients found 23 with clonality of EBV DNA(EBV genome termini), 15 had clonal rearrangement of T cell receptor (TCR) genes, and 7 were cytogenetically abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/121\">",
"     121",
"    </a>",
"    ]. Although three-year survivals for the EBV-positive and TCR-clonal patients were 64 and 53 percent, respectively, none of the seven patients with cytogenetic abnormalities survived.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL AND PATHOLOGIC FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial signs and symptoms of HLH are the same as, or mimic, common infections, fever of unknown origin, or hepatitis. Accordingly, the diagnosis of HLH may be made late in the course of the disease, or may be made only on postmortem examination. In a Swedish study, prominent early clinical signs included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &mdash; 91 percent",
"     </li>",
"     <li>",
"      Hepatomegaly &mdash; 90 percent",
"     </li>",
"     <li>",
"      Splenomegaly &mdash; 84 percent",
"     </li>",
"     <li>",
"      Neurologic symptoms &mdash; 47 percent",
"     </li>",
"     <li>",
"      Rash &mdash; 43 percent",
"     </li>",
"     <li>",
"      Lymphadenopathy &mdash; 42 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these patients have clinical and radiologic findings similar to the acute respiratory distress syndrome, with alveolar-interstitial opacities and pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/122\">",
"     122",
"    </a>",
"    ]. Ultrasonography may show gall bladder wall thickening, hyperechoic kidneys, ascites, and hepatosplenomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HLH simulating other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of HLH may simulate a number of common conditions, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Febrile illness",
"      </strong>",
"      &mdash; A review of 19 patients seen over a 10-year period at one institution showed that clinical and laboratory findings of HLH were present in the first two weeks of the patients' presentation with a febrile illness, before the diagnosis of HLH was made [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/123\">",
"       123",
"      </a>",
"      ]. This paper presents an algorithm for evaluating patients with fever of unknown origin, cytopenias, and abnormal liver function who may develop hypotension and respiratory distress and are subsequently found to have HLH.",
"     </li>",
"     <li>",
"      <strong>",
"       Liver disease and coagulopathy",
"      </strong>",
"      &mdash; Hepatomegaly with liver dysfunction is a common finding on presentation. HLH patients who come to autopsy have chronic persistent hepatitis with periportal lymphocytic infiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/124\">",
"       124",
"      </a>",
"      ]. Initially, HLH patients may have only mild elevations in the liver enzymes and bilirubin, while others may present with hepatic failure and initially be cared for by the hepatology service; markedly elevated ferritin levels in the context of cytopenias may turn the differential diagnosis to HLH. Liver enzyme (AST, ALT) levels greater than three times the upper limit have been reported in 50 to 90 percent of HLH patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/8,123,125\">",
"       8,123,125",
"      </a>",
"      ], while lactate dehydrogenase is elevated in 85 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/123\">",
"       123",
"      </a>",
"      ]. Bilirubin levels between 3 and 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      are frequently seen (&gt;80 percent) and raise questions about the need for reducing the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      . Neonates with HLH may present with hydrops fetalis and liver failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/125\">",
"       125",
"      </a>",
"      ]. Hepatic sinusoidal obstruction syndrome (SOS) may arise spontaneously in patients with HLH, and rates of SOS as high as 25 percent are reported in patients with HLH following hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/126\">",
"       126",
"      </a>",
"      ]. Besides low levels of albumin, 95 percent of HLH patients have a disseminated intravascular coagulopathy and frequently require massive amounts of fresh frozen plasma and platelet transfusions to control this complication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/123\">",
"       123",
"      </a>",
"      ]. We find that D-dimer levels are an especially sensitive indicator of HLH activity.",
"     </li>",
"     <li>",
"      <strong>",
"       Multiple organ failure syndrome",
"      </strong>",
"      &mdash; Patients with HLH are also found among those with the multiple organ failure syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/127\">",
"       127",
"      </a>",
"      ]. Seven of the 11 patients with HLH in this series had respiratory failure, six had cardiovascular failure or shock from the capillary leak syndrome, and renal failure occurred in four. Rare cases of nephrotic syndrome have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/128\">",
"       128",
"      </a>",
"      ]; hyponatremia is a frequent finding.",
"     </li>",
"     <li>",
"      <strong>",
"       Child abuse",
"      </strong>",
"      &mdash; HLH may present with central nervous system findings (eg, seizures, coma, retinal hemorrhages) alone or with bone abnormalities suggestive of child abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/129,130\">",
"       129,130",
"      </a>",
"      ]. A panel of screening tests including CBC, liver function tests, and serum ferritin may help identify the rare case of CNS-HLH among the much more frequent victims of abuse. For those with an elevated ferritin, further testing of NK cell function and soluble interleukin-2 receptor is indicated (see below). A prolonged aPTT is not helpful since this has been found in a majority of child abuse victims with brain injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Encephalitis",
"      </strong>",
"      &mdash; Nearly 75 percent of patients with HLH have central nervous system symptoms mimicking chronic encephalitis that may dominate the clinical picture and develop prior to the appearance of other signs and symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/132,133\">",
"       132,133",
"      </a>",
"      ]. These may include seizures, decreased sensorium, brainstem symptoms, or ataxia. Two FHL patients who presented with only severe encephalitis were reported to have a new missense mutation in the perforin gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/134\">",
"       134",
"      </a>",
"      ]. Another child had a demyelinating peripheral neuropathy caused by diffuse infiltration of the nerve sheath by macrophages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/135\">",
"       135",
"      </a>",
"      ]. Patients may have a mononuclear pleocytosis of the cerebral spinal fluid (lymphocytic meningitis) and evidence of parameningeal infiltrations, subdural effusions, retinal hemorrhages, and hypodense or necrotic areas, demonstrated by magnetic resonance imaging of the brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/136\">",
"       136",
"      </a>",
"      ]. In a report from the Histiocyte Society, children with an abnormal CSF had an increased risk for mortality and neurologic sequelae [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic findings of HLH result from the aggressive proliferation of normal histiocytes and T-lymphocytes in various tissues. Hemophagocytosis of red cells (erythrophagocytosis), other white blood cells, or platelets in the bone marrow, spleen, or lymph nodes is the key diagnostic finding (",
"    <a class=\"graphic graphic_picture graphicRef81067 \" href=\"mobipreview.htm?17/30/17890\">",
"     picture 1",
"    </a>",
"    ). In nearly 20 percent of cases, more than one specimen may be required in order to demonstrate this phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/2\">",
"     2",
"    </a>",
"    ]. The macrophages in HLH do not have the cellular atypia associated with malignant histiocytes, and they are clearly a different cell from the CD1a-staining Langerhans cell of Langerhans cell histiocytosis (formerly called Histiocytosis-X).",
"   </p>",
"   <p>",
"    Infiltration of the liver and bone marrow with histiocytes and the antiproliferative effects of cytokines (see below) result in damage to these organs. Hepatic failure is a prominent feature in many patients, who may demonstrate markedly elevated liver enzyme levels, hyperbilirubinemia, hypoalbuminemia, as well as decreased activity of various clotting factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. Four histopathologic patterns were observed: chronic hepatitis-like; leukemia-like; histiocytic storage disorder-like; and neonatal giant cell hepatitis-like [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because HLH is often fatal, one must have a high index of suspicion in patients who present with several of the following: high fevers, maculopapular rash, failure to thrive, central nervous system symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, coagulopathy, abnormal liver function tests, and high serum ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/1,2,30,141\">",
"     1,2,30,141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HLH is dependent on a defined set of presenting major signs and symptoms, including the following (",
"    <a class=\"graphic graphic_table graphicRef80721 \" href=\"mobipreview.htm?25/0/25612\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Splenomegaly",
"     </li>",
"     <li>",
"      Cytopenia in at least two cell lines",
"     </li>",
"     <li>",
"      Hypertriglyceridemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypofibrinogenemia. Triglycerides may not be elevated until the liver has been affected for some time. In a review of patients with HLH associated with viral infections, lymphoma, autoimmune disease, or post-transplant, 68 percent had elevated triglycerides at diagnosis or during the course of the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/142\">",
"       142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tissue demonstration of hemophagocytosis (repeated attempts to identify the characteristic histology in lymph node biopsy or bone marrow aspirates may be necessary). In nearly 20 percent of cases, documenting hemophagocytosis on the first bone marrow specimen is difficult or impossible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/2\">",
"       2",
"      </a>",
"      ]. However, inability to demonstrate hemophagocytosis on the initial specimen should not prevent prompt institution of treatment, provided that other clinical criteria are fulfilled (",
"      <a class=\"graphic graphic_table graphicRef80721 \" href=\"mobipreview.htm?25/0/25612\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/143\">",
"       143",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not listed in the diagnostic criteria, nearly all of these patients will have hepatitis as manifested by elevated liver enzymes and bilirubin and decreased coagulation factors.",
"   </p>",
"   <p>",
"    Based on biologic and molecular findings from the HLH-94 study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/1,144\">",
"     1,144",
"    </a>",
"    ], patients with a molecular diagnosis of HLH (ie, when DNA analysis reveals a mutation in the perforin gene that has been associated with HLH) do not need to fulfill all the other diagnostic criteria listed immediately above.",
"   </p>",
"   <p>",
"    Additional criteria for the diagnosis of HLH include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low or absent NK-cell activity",
"     </li>",
"     <li>",
"      Serum ferritin concentration &gt;500",
"      <span class=\"nowrap\">",
"       microg/L",
"      </span>",
"      (although a review of ferritin values at the author&rsquo;s institution suggested levels above 3000",
"      <span class=\"nowrap\">",
"       microg/L",
"      </span>",
"      were more specific) (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Ferritin levels'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Elevated levels of soluble CD25 (alpha chain of sIL-2 receptor) &gt;2 SD above the mean; usually &gt;2400",
"      <span class=\"nowrap\">",
"       U/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Either the first of these three additional criteria, or a combination of the second and third, may substitute for one of the major clinical criteria listed above. However, there are a few caveats with the use of these criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since sIL-2 levels vary greatly according to age, one must know the age-related normal levels to correctly judge these results (personal communication, Dr. Lisa Filipovich).",
"     </li>",
"     <li>",
"      Regarding NK cell function, patients with the Autoimmune Lymphoproliferative Syndrome (ALPS) have decreased numbers of NK cells and may present with splenomegaly and cytopenias secondary to the presence of autoantibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/145\">",
"       145",
"      </a>",
"      ]. Although there appears to be some overlap, in HLH the defect is a lack of triggering of apoptosis, whereas in ALPS there is a resistance to apoptosis because of mutations in the FAS gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/146\">",
"       146",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Japan of 20 neonates diagnosed with HLH, hypertriglyceridemia and neutropenia were uncommon (15 to 30 percent); the incidence of fever was extremely low in the 8 preterm infants (12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/147\">",
"       147",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Ferritin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a differential diagnostic point, a review of the literature showed that ferritin levels &gt;500",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    were rarely found in patients with infectious or other diseases unless they were receiving chronic red cell transfusions, or had hemochromatosis or a rheumatologic disorder.",
"   </p>",
"   <p>",
"    However, patients with systemic lupus erythematosus may have elevated serum ferritin levels, with some as high as 4000",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/148\">",
"     148",
"    </a>",
"    ]. In HLH or adult Still's disease patients, the glycosylated ferritin is less than 20 percent of the total ferritin concentration as opposed to normal patients in whom glycosylation is found on 50 to 80 percent of the ferritin molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. Results from the HLH-94 study indicated that a ferritin level &gt;500",
"    <span class=\"nowrap\">",
"     microg/L",
"    </span>",
"    was 80 percent specific for the diagnosis of HLH.",
"   </p>",
"   <p>",
"    A retrospective two-year review of all patients admitted to Texas Children&rsquo;s Hospital, Houston, TX with ferritin levels &gt;500",
"    <span class=\"nowrap\">",
"     microg/liter",
"    </span>",
"    was performed in order to define the specificity and sensitivity of ferritin levels in the diagnosis of HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/151\">",
"     151",
"    </a>",
"    ]. Ferritin concentrations &gt;500",
"    <span class=\"nowrap\">",
"     microg/liter",
"    </span>",
"    were 100 percent sensitive for HLH. However, at this modest level, there is considerable overlap with many other diagnoses. Ferritin concentrations &gt;10,000",
"    <span class=\"nowrap\">",
"     microg/liter",
"    </span>",
"    were 90 percent sensitive and 96 percent specific for HLH, with very minimal overlap with sepsis, infections, and liver failure.",
"   </p>",
"   <p>",
"    Another review of HLH patients treated at the author&rsquo;s institution showed that the rate of decline of ferritin has prognostic implications for response to therapy. Patients with percent ferritin decreases less than 50 percent compared with those with 96 percent or greater had an odds ratio for dying of 17.42 (90% CI 1.65-184). Higher maximum ferritin levels (&gt;11,000",
"    <span class=\"nowrap\">",
"     microg/liter)",
"    </span>",
"    in the first three weeks also contributed to the odds of death (OR=5.6; 90%CI 1.2-24.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Specialized testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized tests that may be helpful in supporting the diagnosis of HLH include histologic evidence of chronic persistent hepatitis, low perforin expression and low natural killer cell activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/84\">",
"     84",
"    </a>",
"    ], coagulopathy with markedly prolonged activated partial thromboplastin time, and increased concentrations of circulating soluble interleukin (IL)-2 (sIL-2R) receptor (sCD25). In one study, sIL-2R levels &gt;10,000",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    were associated with a 36 percent survival versus 78 percent when the sIL-2R was &lt;10,000",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated circulating serum levels of neuron-specific enolase (NSE) were thought to originate from macrophages stimulated with gamma interferon and soluble IL-2 receptor or partly from the destruction of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/154\">",
"     154",
"    </a>",
"    ]. Serum NSE levels were found to be inversely proportional to the platelet count, and sequential changes in NSE levels appeared to reflect the clinical course.",
"   </p>",
"   <p>",
"    The soluble hemoglobin-haptoglobin scavenger receptor CD163 that is specific for macrophages is a new marker for HLH disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/155\">",
"     155",
"    </a>",
"    ]. Its levels track closely with disease activity and correlate with serum ferritin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients in whom the diagnosis of HLH is suspected, referral to a hematology-oncology specialist is urgently required in order to initiate immunochemotherapy on the HLH-94 protocol (",
"    <a class=\"graphic graphic_algorithm graphicRef65737 \" href=\"mobipreview.htm?16/42/17071\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment should be initiated immediately when the patient fulfills the clinical criteria for HLH (",
"    <a class=\"graphic graphic_table graphicRef80721 \" href=\"mobipreview.htm?25/0/25612\">",
"     table 1",
"    </a>",
"    ), since delay of therapy may lead to irreversible multi-organ failure. Gene mutation studies should be sent when clinical criteria are met, but treatment should not be delayed pending the results, which may dictate the need for hematopoietic cell transplantation later in the patient's course. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The standard of care in 2011 for HLH patients being treated outside of a therapeutic research trial is treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , as outlined in the HLH-94 trial.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    may be added (initial dose 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, divided in two daily doses; target trough levels 200",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    but the benefit of its use during the initial eight-week induction period is not yet proven and its use has been associated with posterior reversible encephalopathy syndrome (PRES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/156\">",
"     156",
"    </a>",
"    ]. In the HLH-2004 research protocol, cyclosporine will be started on day one. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'HLH-2004 protocol'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     HLH-94 protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until the advent of the HLH-94 protocol, therapy for these children had been frustratingly ineffective, with over 90 percent fatalities. The HLH-94 protocol included induction therapy over an eight-week period with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (VP-16), and intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (trough levels of 200",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    started at week 9, along with pulses of dexamethasone and etoposide for up to one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/144\">",
"     144",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      ��� 10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for the first two weeks; 5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day weeks 3 to 4; 2.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day weeks 5 to 6; 1.25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      during week 7; tapering to zero over the eighth week.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      ��� 150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenously",
"      <sup>",
"      </sup>",
"      twice weekly for the first two weeks; then once weekly for a total of eight weeks.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      ��� Intrathecal methotrexate and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      are administered at a maximum of four doses (weekly during weeks 3 through 6) only if there were progressive neurological symptoms or if an abnormal cerebrospinal fluid had not improved. Methotrexate doses by age: 6 mg for &lt;1 year; 8 mg for 1 to 2 years; 10 mg for 2 to 3 years; 12 mg each dose for &gt;3 years. Hydrocortisone doses by age: 4 mg for &lt;1 year; 6 mg for 1 to 2 years; 8 mg for 2 to 3 years; 10 mg &gt;3 years.",
"     </li>",
"     <li>",
"      <strong>",
"       Supportive therapy",
"      </strong>",
"      ��� Antimycotic treatment was recommended during the initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      therapy along with continuous cotrimoxazole treatment, equivalent to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      three times weekly, as prophylaxis against infection with Pneumocystis jirovecii.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients who can be treated with chemotherapy alone will have reached a clinical remission by the tenth week of therapy. Results of this study showed an overall survival of 55 percent at a median follow-up of 3.1 years. This therapy may be sufficient for children who have no NK cell defects, no evidence for familial HLH, or whose HLH is clearly secondary to an infection (",
"    <a class=\"graphic graphic_algorithm graphicRef65737 \" href=\"mobipreview.htm?16/42/17071\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    EBV-HLH patients treated with the HLH-94 protocol did better than those only given steroids, immunoglobulin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/157\">",
"     157",
"    </a>",
"    ]. In a longitudinal study of EBV-HLH patients in Japan it was reported that nearly 20 percent had a reactivation and 19 out of 78 patients died of hemorrhage, infection, late reactivation, transplant-associated causes, or secondary leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/158\">",
"     158",
"    </a>",
"    ]. Liver transplantation is a therapeutic option for young children with fulminant hepatic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The additional improvement to the cure of HLH that is supplied by the use of cyclosporin in the HLH-94 protocol is unproven. Accordingly the author does not use cyclosporin at any time. (See",
"    <a class=\"local\" href=\"#H13762518\">",
"     'Use of cyclosporin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4600202\">",
"    <span class=\"h3\">",
"     Long-term results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total of 249 subjects (median age 8 months, range zero to 15 years) fulfilled inclusion criteria for the HLH-94 protocol and started therapy between July 1994 and December 2003. Of this total, 227 (91 percent) had five or more years of follow-up. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/160\">",
"     160",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 6.2 years, the estimated five-year probability of survival was 54 &plusmn; 6 percent. Death before hematopoietic cell transplantation (HCT) occurred in 72 subjects (29 percent). Sixty-four of the 72 died within one year, 97 percent of whom had active disease. Overall, 71 percent of the enrolled subjects were successfully treated by HLH-94 such that they either received HCT or achieved long-term remission without HCT.",
"     </li>",
"     <li>",
"      The 35 subjects (median age four months) who died during the first two months of treatment more often had jaundice, edema, and elevated creatinine. The 49 subjects who were alive without signs of disease activity and off therapy for more than one year without HCT, presented at a significantly older age (median age 24 months), were more often female, and less often had CNS disease and hepatomegaly.",
"     </li>",
"     <li>",
"      In the 124 subjects who underwent HCT, five-year survival was 66 &plusmn; 8 percent. There was a non-significant trend for increased survival in those who had nonactive disease at the time of HCT (p = 0.064).",
"     </li>",
"     <li>",
"      Subjects with familial disease had a five-year survival of 50 &plusmn; 13 percent. None survived without HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the HLH-94 protocol provided a dramatic improvement in survival of HLH patients, from near zero to over 55 percent, there is obviously need for further improvements. Increased awareness by physicians, as well as improved diagnostic techniques, could prevent early deaths. New therapeutic strategies are being developed to control the disease when standard therapies are not sufficient. One such strategy is to use the anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/6\">",
"     6",
"    </a>",
"    ]. One study has reported that alemtuzumab improved survival by decreasing HLH activity in patients (77 percent) before stem cell transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) appears to provide the best overall cure rate in HLH. This therapy is needed for all patients who have homozygous mutations in the various genes associated with HLH, those who responded poorly to the initial eight weeks of chemotherapy, and those with CNS disease. Most experts agree that prompt institution of immunochemotherapy through the use of all three agents listed above, followed by allogeneic HCT, provides the optimal chance for long-term disease control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/121,162-166\">",
"     121,162-166",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report is available on results in 86 children who received therapy with the HLH-94 protocol followed by allogeneic HCT between 1995 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/165\">",
"     165",
"    </a>",
"    ]. Estimated three-year overall survival post-HCT was 71, 70, 50, and 54 percent for those with a matched related donor, matched unrelated donor, family haploidentical donor, and mismatched unrelated donor, respectively. Mortality was predominantly transplant-related. When compared with those having inactive disease, the estimated odds ratio for death was 2.75 (95% CI 1.3-6.0) and 1.80 (95% CI 0.8-4.1) for those with active disease after two months of therapy or at the time of HCT, respectively.",
"   </p>",
"   <p>",
"    At a median follow-up time of 4.1 years post-HCT, 55 of the original 86 patients were still alive (64 percent) without active disease. Their quality of life was assessed by \"ability to play\", which was normal, mild to moderately inhibited, or moderately to severely inhibited in 83, 13, and 4 percent, respectively. Chronic graft versus host disease (GVHD) occurred in 9 percent of patients overall, with the highest proportion (2 of 6) noted in those with haploidentical transplants.",
"   </p>",
"   <p>",
"    The largest single center study of HCT for HLH (48 consecutive patients) was reported by a French group, using the same conditioning regimen for most patients as reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/167\">",
"     167",
"    </a>",
"    ]. At a median follow-up of 5.8 years (maximum 20 years), overall survival was 58 percent. If the patient had no active HLH at the time of HCT, the type of donor (matched versus partially matched) had no influence. However, for those patients with active disease at the time of HCT, engraftment occurred in only 46 percent of patients with haploidentical donors versus 88 percent with matched related or matched unrelated donors. Chronic GVHD occurred in 6 percent of patients with one transplant and in 14 percent of those requiring a second transplant.",
"   </p>",
"   <p>",
"    Results of treatment of 91 HLH patients transplanted in the United States have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/168\">",
"     168",
"    </a>",
"    ]. Patients who had no active HLH at the time of transplantation had a 50 percent long term survival, whereas those with active HLH had only 20 percent survival. The",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"      busulfan",
"     </a>",
"     /cytoxan/VP-16",
"    </span>",
"    regimen was employed for conditioning. Given improvements in HCT procedures, these studies indicate that a patient with HLH and active disease can still be a candidate for potentially curative transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19767724\">",
"    <span class=\"h4\">",
"     Reduced-intensity transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced-intensity (non-myeloablative) HCT using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    combinations was attempted in a series of 12 patients with HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/164\">",
"     164",
"    </a>",
"    ]. All showed engraftment at a median time of 14 days. At a median follow-up of 30 months, 9 of the 12 (75 percent) were alive and in complete remission; chronic GVHD was present in three of the 12. A further report from these authors in 23 patients with HLH indicated that 84 percent were alive and in remission at a median follow-up of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/170\">",
"     170",
"    </a>",
"    ]. In a separate report, 26 patients with HLH received non-myeloablative HCT with fludarabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/171\">",
"     171",
"    </a>",
"    ]. Although 65 percent developed mixed",
"    <span class=\"nowrap\">",
"     donor/recipient",
"    </span>",
"    chimerism, estimated overall three-year survival for the entire group was 92 percent.",
"   </p>",
"   <p>",
"    While randomized studies comparing myeloablative to reduced intensity HCT have not been performed, the consensus among those who perform HCT in patients with HLH is that reduced-intensity HCT is superior to myeloablative HCT and will be recommended in future protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     HLH-2004 protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new version of the HLH treatment program was initiated in January 2004, with the following aims [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To provide and evaluate a revised treatment protocol for initial and continuation therapy, with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      started on day one, rather than at week 9, as in the HLH-94 protocol. The aim is to initiate and maintain an acceptable clinical condition, in order to perform a curative hematopoietic cell transplantation (HCT) for patients with familial, relapsing, or severe and persistent HLH.",
"     </li>",
"     <li>",
"      To evaluate and improve the results of HCT for various types of HCT donors and evaluate the prognostic importance of the state of remission at the time of HCT.",
"     </li>",
"     <li>",
"      To evaluate long-term neurologic complications of those with or without central nervous system findings.",
"     </li>",
"     <li>",
"      To improve understanding of the pathophysiology of this disorder through biologic studies of the genetics, cytotoxicity, and prognostic value of NK cell activity subtyping.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HLH-2004 protocol",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00426101?term=NCT00426101&amp;rank=1\">",
"     NCT00426101",
"    </a>",
"    was closed December 31, 2011. Treatment recommendations can be found at",
"    <a class=\"external\" href=\"file://www.histiocytesociety.org/\">",
"     www.histiocytesociety.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13762518\">",
"    <span class=\"h3\">",
"     Use of cyclosporin",
"    </span>",
"    &nbsp;&mdash;&nbsp;While use of cyclosporin starting on day one was an important part of the HLH-2004 protocol, the author recommends not using cyclosporin in the first eight weeks of treatment because of potential neurotoxicity, especially with patients who have hypertension, liver or renal failure. Use of cyclosporin starting at week 9, as per the HLH-94 protocol, is safer, but the additional improvement to the cure of HLH is unproven. Accordingly, the author does not use cyclosporin at any time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Indications and general supportive care issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical that all treating physicians, as well as potential patients, be registered with the Histiocyte Society Study before the protocol can be released, so that patient safety issues, responses, toxicity, and biologic questions can be answered.",
"   </p>",
"   <p>",
"    The author recommends the HLH-1994 protocol for patients who fit the diagnostic criteria for HLH (",
"    <a class=\"graphic graphic_table graphicRef80721 \" href=\"mobipreview.htm?25/0/25612\">",
"     table 1",
"    </a>",
"    ) with the following exceptions (",
"    <a class=\"graphic graphic_algorithm graphicRef65737 \" href=\"mobipreview.htm?16/42/17071\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic juvenile idiopathic arthritis and lupus patients with the macrophage activation syndrome (MAS); treatment of MAS is discussed below.",
"     </li>",
"     <li>",
"      HIV-associated HLH",
"     </li>",
"     <li>",
"      Iatrogenically immune-suppressed patients. Even these patients may need to have the full treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      if they do not respond to less aggressive treatment regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aggressive supportive care is needed with red cell, platelet, and fresh frozen plasma transfusions, antibiotics, and nutritional support. In the past, many of these children died of fungal or bacterial infections, although with vigilant care this is less likely. Prophylactic bactrim and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    are routinely given; splenectomy is indicated only if the patient is having life-threatening respiratory problems secondary to an enlarged spleen. Many of these patients require admission to the intensive care unit where, despite mechanical ventilation, vasoactive agents, and renal replacement, the mortality is 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/172\">",
"     172",
"    </a>",
"    ]. Shock at the time of ICU admission and a platelet count",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL",
"    </span>",
"    are associated with a fourfold increased chance of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2011387\">",
"    <span class=\"h3\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) has only modest activity in the macrophage activation syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/173,174\">",
"     173,174",
"    </a>",
"    ] and typical HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/175\">",
"     175",
"    </a>",
"    ]. Its use was not a part of the HLH-2004 protocol. We do not recommend its use during the first eight weeks of the illness. After eight weeks, we use it in a supportive role in a dose of 500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once per month.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific long-term follow-up guidelines after treatment of childhood cancer and HLH patients treated with chemotherapy have been published by the Children's Oncology Group, and are available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/176\">",
"     176",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other treatment approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antithymocyte globulin (ATG), corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been reported in 38 consecutive patients with familial HLH, one-half of whom went on to receive hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/177\">",
"     177",
"    </a>",
"    ]. Overall survival for the entire group was 55 percent.",
"   </p>",
"   <p>",
"    A hybrid treatment approach (the HIT-HLH Trial) which combines the use of ATG,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    is currently under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MACROPHAGE ACTIVATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macrophage activation syndrome (MAS), is a severe and life-threatening complication seen in patients with systemic juvenile idiopathic arthritis (sJIA) or systemic lupus erythematosus (SLE), and has most of the clinical features of HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/179\">",
"     179",
"    </a>",
"    ]. It has been considered by some authors as an acquired (secondary) form of HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/179,180\">",
"     179,180",
"    </a>",
"    ]. Interestingly, a few children with systemic onset JIA have been found to have heterozygotic expression of some of the genetic abnormalities associated with HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/181\">",
"     181",
"    </a>",
"    ]. A report of marked elevations of soluble cytokines in some children with MAS suggests uncontrolled proliferation of cytotoxic T lymphocytes (CD8+), which is also characteristic of HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/182\">",
"     182",
"    </a>",
"    ]. However, this author prefers that the separate term MAS be used for such patients.",
"   </p>",
"   <p>",
"    MAS typically occurs in sJIA within the first few days or weeks following the initiation of therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , other nonsteroidal anti-inflammatory drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , or gold salts. This complication also may follow viral and bacterial infections, or occur without any evident initiating event. Children may present with spontaneous bleeding, bruising, or shock. Hemoglobin, platelet count, and serum fibrinogen typically drop precipitously secondary to consumptive coagulopathy. Fibrin split products in the peripheral circulation are generally the earliest confirmatory sign of MAS. Viral infections such as EBV or CMV may trigger MAS. Although some cases of MAS in patients with systemic onset JIA and renal failure have a fatal outcome, survival has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/183\">",
"     183",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39994?source=see_link&amp;anchor=H24#H24\">",
"     \"Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis\", section on 'T cell contribution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to classical HLH, MAS is characterized by proliferation of macrophages and T-lymphocytes resulting in continuous fever, purpura, hepatosplenomegaly, mental status changes, prolongations in the prothrombin time (PT) and the activated partial thromboplastin time (aPTT),",
"    <strong>",
"     hypofibrinogenemia",
"    </strong>",
"    , and a",
"    <strong>",
"     reduced",
"    </strong>",
"    erythrocyte sedimentation rate (ESR). Since patients with systemic JIA often have thrombocytosis and leucocytosis, a &ldquo;relative&rdquo; decrease in those levels is more likely than frank thrombocytopenia and leukopenia, as seen in classic HLH. Patients with MAS have markedly elevated levels of activated macrophages as assayed by soluble CD 163 (sCD 163) and expansion of T cells noted by elevated soluble interleukin 2 receptor alpha levels (sIL-2Ra) that are higher than the elevations in patients with sJIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/182\">",
"     182",
"    </a>",
"    ]. These markers may be useful to identify patients with subclinical MAS.",
"   </p>",
"   <p>",
"    Clinical and laboratory findings in MAS contrast with those seen in an exacerbation of JIA, which is characterized by daily or twice-daily fevers,",
"    <strong>",
"     hyperfibrinogenemia",
"    </strong>",
"    , leukocytosis, thrombocytosis, and an",
"    <strong>",
"     increased",
"    </strong>",
"    ESR. JIA patients may have systemic onset disease with single or multiple joint involvement and may be newly diagnosed or chronic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of 74 reported cases of MAS in children with systemic JIA separated patients with MAS from those without MAS based on the following clinical and laboratory findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/184\">",
"     184",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical findings: Patients with MAS were more likely to have hemorrhage (purpura, easy bruising, and mucosal bleeding)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      central nervous system dysfunction (irritability, disorientation, lethargy, headache, seizures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coma).",
"     </li>",
"     <li>",
"      Laboratory findings: Patients with MAS were more likely to have laboratory findings of thrombocytopenia (&le;150,000 cells per microL), leukopenia (&le;4000 cells per microL), low fibrinogen levels (&le;2.5 g per L), and increased aspartate aminotransferase levels (&ge;40 U per L).",
"     </li>",
"     <li>",
"      Two or more of the above-noted abnormal laboratory findings best differentiated those patients with MAS from those without MAS. The second best separation was provided by the presence of two or more of the above-noted clinical findings along with one of the laboratory abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gene expression profiling of sJIA patients with and without MAS reveal activation of genes involved with synthesis of hemoglobins and red cell membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/185\">",
"     185",
"    </a>",
"    ]. Another cluster of genes was enriched for cell cycle regulation and another with negative regulation of T cells.",
"   </p>",
"   <p>",
"    Polymorphisms of the MUNC13-4 gene have been identified in 56 percent of patients with",
"    <span class=\"nowrap\">",
"     sJIA/MAS",
"    </span>",
"    as opposed to 12 percent of healthy controls and 8 percent of sJIA with no MAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with systemic onset JIA and MAS can have defective NK cell function and low perforin expression identical to that seen in HLH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/187\">",
"     187",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Perforin expression'",
"    </a>",
"    above.) The most profound abnormalities occur in the JIA patients with systemic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/188\">",
"     188",
"    </a>",
"    ]. NK cell activity was two standard deviations below pediatric controls in 50 percent of patients with systemic onset JIA and only 1 out of 20 with non-systemic JIA. Perforin expression in NK cells or cytotoxic T lymphocytes was not statistically different between the clinical subgroups.",
"   </p>",
"   <p>",
"    Although tumor necrosis factor (TNF)-alpha has been thought to be an important cytokine in promoting HLH or MAS, there are two surprising cases of MAS developing in patients with juvenile idiopathic arthritis who received treatment with an anti-TNF antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/189,190\">",
"     189,190",
"    </a>",
"    ]. It appears that neutralization of TNF is not sufficient for treatment of HLH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of MAS consists of fresh frozen plasma, corticosteroids, and supportive care. All NSAIDs and other antirheumatic medications except corticosteroids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    should be withdrawn since they may exacerbate the illness. Two reports suggest that cyclosporine is uniquely effective in this setting, even when corticosteroids appear ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/191,192\">",
"     191,192",
"    </a>",
"    ]. Anti-TNF agents might help control MAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/193\">",
"     193",
"    </a>",
"    ], but, as noted above, these medications have also been associated with the development of MAS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/190\">",
"     190",
"    </a>",
"    ]. The macrophage activation syndrome (MAS) has been successfully treated with intravenous, followed by oral, cyclosporine at doses of 2 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Steroids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) are often already being used in these patients. If not, they should be added. Suggested doses for prednisone are 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and for dexamethasone 6",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    Following this treatment patients usually become afebrile within the first two days, with improved blood counts in one to eight days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/5/41050/abstract/191\">",
"     191",
"    </a>",
"    ]. If there is no response to this treatment, use of the HLH-2004 protocol (see",
"    <a class=\"local\" href=\"#H29\">",
"     'HLH-2004 protocol'",
"    </a>",
"    above) is recommended (",
"    <a class=\"graphic graphic_algorithm graphicRef65737 \" href=\"mobipreview.htm?16/42/17071\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17796965\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal disorder of children and adults due to cytokine dysfunction, resulting in uncontrolled accumulation of activated T-lymphocytes and activated histiocytes (macrophages) in many organs. HLH may be familial, associated with a number of different infections, autoimmune disorders, or coincident with a number of malignancies. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17796972\">",
"    <span class=\"h2\">",
"     When to suspect and diagnose HLH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial signs and symptoms of HLH are the same as, or mimic, common infections, fever of unknown origin, or hepatitis. HLH should be suspected in those with fever, splenomegaly, cytopenias, elevated triglyceride and ferritin levels, and hemophagocytosis demonstrated in bone marrow, spleen, or lymph nodes. Diagnostic criteria for HLH are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef80721 \" href=\"mobipreview.htm?25/0/25612\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17796979\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLH may simulate a number of conditions, such as infectious fever, hepatitis, encephalitis, multiple organ failure syndrome, and acute respiratory distress syndrome. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'HLH simulating other conditions'",
"    </a>",
"    above.) A similar condition, macrophage activation syndrome (MAS) may be seen in patients with systemic juvenile idiopathic arthritis or systemic lupus erythematosus. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Macrophage activation syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17796986\">",
"    <span class=\"h2\">",
"     Treatment of HLH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be initiated immediately when the patient fulfills the clinical criteria for HLH, since delay of therapy may lead to irreversible multi-organ failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef65737 \" href=\"mobipreview.htm?16/42/17071\">",
"       algorithm 1",
"      </a>",
"      ) indicates our recommended initial treatment for HLH (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If possible, most patients should be treated with the HLH-94 protocol. The standard of care for HLH patients being treated outside of a therapeutic research trial is initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , as outlined in the HLH-94 protocol. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suggested initial treatment for the macrophage activation syndrome (MAS) includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      plus a corticosteroid. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allogeneic hematopoietic cell transplantation is needed for all patients who have homozygous mutations in the various genes associated with HLH, those who responded poorly to the initial eight weeks of chemotherapy, and those with CNS disease. Most experts agree that prompt institution of immunochemotherapy through the use of the agents listed above (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ), followed by allogeneic HCT, provides the optimal chance for long-term disease control. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/1\">",
"      Henter JI, Horne A, Aric&oacute; M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/2\">",
"      Aric&ograve; M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia 1996; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/3\">",
"      Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988; 67:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/4\">",
"      Clementi R, Emmi L, Maccario R, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood 2002; 100:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/5\">",
"      Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 2004; 124:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/6\">",
"      Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118:4041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/7\">",
"      Henter JI, Elinder G, S&ouml;der O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/8\">",
"      Niece JA, Rogers ZR, Ahmad N, et al. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr Blood Cancer 2010; 54:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/9\">",
"      McClain K, Gehrz R, Grierson H, et al. Virus-associated histiocytic proliferations in children. Frequent association with Epstein-Barr virus and congenital or acquired immunodeficiencies. Am J Pediatr Hematol Oncol 1988; 10:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/10\">",
"      Chen TL, Wong WW, Chiou TJ. Hemophagocytic syndrome: an unusual manifestation of acute human immunodeficiency virus infection. Int J Hematol 2003; 78:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/11\">",
"      Fardet L, Blum L, Kerob D, et al. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. Clin Infect Dis 2003; 37:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/12\">",
"      Grossman WJ, Radhi M, Schauer D, et al. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood 2005; 106:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/13\">",
"      Huang DB, Wu JJ, Hamill RJ. Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDS. Scand J Infect Dis 2004; 36:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/14\">",
"      Risdall RJ, Brunning RD, Hernandez JI, Gordon DH. Bacteria-associated hemophagocytic syndrome. Cancer 1984; 54:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/15\">",
"      Yoshioka M, Kikuta H, Ishiguro N, et al. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome. J Med Virol 2003; 70:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/16\">",
"      Chuang HC, Lay JD, Hsieh WC, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 2005; 106:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/17\">",
"      Toga A, Wada T, Sakakibara Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis 2010; 201:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/18\">",
"      Mou SS, Nakagawa TA, Riemer EC, et al. Hemophagocytic lymphohistiocytosis complicating influenza A infection. Pediatrics 2006; 118:e216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/19\">",
"      Harms PW, Schmidt LA, Smith LB, et al. Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol 2010; 134:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/20\">",
"      Wong KF, Hui PK, Chan JK, et al. The acute lupus hemophagocytic syndrome. Ann Intern Med 1991; 114:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/21\">",
"      Morris JA, Adamson AR, Holt PJ, Davson J. Still's disease and the virus-associated haemophagocytic syndrome. Ann Rheum Dis 1985; 44:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/22\">",
"      Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003; 49:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/23\">",
"      Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/24\">",
"      Ezdinli EZ, Kucuk O, Chedid A, et al. Hypogammaglobulinemia and hemophagocytic syndrome associated with lymphoproliferative disorders. Cancer 1986; 57:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/25\">",
"      Arico M, Imashuku S, Clementi R, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001; 97:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/26\">",
"      Rohr J, Beutel K, Maul-Pavicic A, et al. Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica 2010; 95:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/27\">",
"      Karras A, Thervet E, Legendre C, Groupe Coop&eacute;ratif de transplantation d'Ile de France. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation 2004; 77:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/28\">",
"      Llad&oacute; L, Figueras J, Com&iacute; S, et al. Haemophagocytic syndrome after liver transplantation in adults. Transpl Int 2004; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/29\">",
"      George TI, Jeng M, Berquist W, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature. Pediatr Blood Cancer 2005; 44:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/30\">",
"      Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/31\">",
"      M&eacute;nasch&eacute; G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000; 25:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/32\">",
"      Enders A, Zieger B, Schwarz K, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006; 108:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/33\">",
"      Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 1990; 75:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/34\">",
"      Okuda T, Sakamoto S, Deguchi T, et al. Hemophagocytic syndrome associated with aggressive natural killer cell leukemia. Am J Hematol 1991; 38:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/35\">",
"      Miyahara M, Sano M, Shibata K, et al. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol 2000; 79:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/36\">",
"      Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma 2000; 38:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/37\">",
"      Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 2000; 111:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/38\">",
"      M&eacute;nard F, Besson C, Rinc&eacute; P, et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis 2008; 47:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/39\">",
"      O'Brien MM, Lee-Kim Y, George TI, et al. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/40\">",
"      Rubin CM, Burke BA, McKenna RW, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985; 56:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/41\">",
"      Marzano AV, Berti E, Paulli M, Caputo R. Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol 2000; 136:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/42\">",
"      Craig AJ, Cualing H, Thomas G, et al. Cytophagic histiocytic panniculitis--a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature. J Am Acad Dermatol 1998; 39:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/43\">",
"      Takagi S, Masuoka K, Uchida N, et al. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol 2009; 147:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/44\">",
"      Khandelwal A, Shah NB, Eichenseer P, et al. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol 2008; 6:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/45\">",
"      Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/46\">",
"      Kaito K, Kobayashi M, Katayama T, et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997; 59:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/47\">",
"      Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003; 49:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/48\">",
"      Shin HJ, Chung JS, Lee JJ, et al. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci 2008; 23:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/49\">",
"      Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematol Oncol 2011; 29:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/50\">",
"      Fox CP, Shannon-Lowe C, Gothard P, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 2010; 51:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/51\">",
"      Su IJ, Hsu YH, Lin MT, et al. Epstein-Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis. Cancer 1993; 72:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/52\">",
"      Allory Y, Challine D, Haioun C, et al. Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution. Am J Surg Pathol 2001; 25:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/53\">",
"      Shimizu Y, Tanae K, Takahashi N, et al. Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. Leuk Res 2010; 34:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/54\">",
"      Hot A, Toh ML, Copp&eacute;r&eacute; B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore) 2010; 89:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/55\">",
"      Tabata R, Tabata C, Terada M, Nagai T. Hemophagocytic syndrome in elderly patients with underlying autoimmune diseases. Clin Rheumatol 2009; 28:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/56\">",
"      Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 2008; 47:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/57\">",
"      Nagafuji K, Nonami A, Kumano T, et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 2007; 92:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/58\">",
"      Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 2011; 118:5794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/59\">",
"      Pachlopnik Schmid J, Schmid JP, C&ocirc;te M, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010; 235:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/60\">",
"      Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr 2012; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/61\">",
"      Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004; 104:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/62\">",
"      Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003; 15:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/63\">",
"      Karandikar NJ, Kroft SH, Yegappan S, et al. Unusual immunophenotype of CD8+ T cells in familial hemophagocytic lymphohistiocytosis. Blood 2004; 104:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/64\">",
"      Henter JI, Elinder G, S&ouml;der O, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78:2918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/65\">",
"      Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997; 89:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/66\">",
"      Aric&ograve; M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol 2001; 114:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/67\">",
"      Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 1989; 73:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/68\">",
"      Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 2008; 143:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/69\">",
"      Takada H, Ohga S, Mizuno Y, et al. Increased IL-16 levels in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2004; 26:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/70\">",
"      Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005; 106:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/71\">",
"      Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 2008; 143:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/72\">",
"      Xu XJ, Tang YM, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr 2012; 160:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/73\">",
"      Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 1996; 18:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/74\">",
"      Eife R, Janka GE, Belohradsky BH, Holtmann H. Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol 1989; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/75\">",
"      Ishii E, Ueda I, Shirakawa R, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood 2005; 105:3442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/76\">",
"      Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/77\">",
"      Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119:2754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/78\">",
"      Schneider EM, Lorenz I, M&uuml;ller-Rosenberger M, et al. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 2002; 100:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/79\">",
"      Schneider EM, Lorenz I, Walther P, Janka-Schaub GE. Natural killer deficiency: a minor or major factor in the manifestation of hemophagocytic lymphohistiocytosis? J Pediatr Hematol Oncol 2003; 25:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/80\">",
"      Marcenaro S, Gallo F, Martini S, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 2006; 108:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/81\">",
"      Imashuku S, Hyakuna N, Funabiki T, et al. Low natural killer activity and central nervous system disease as a high-risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis. Cancer 2002; 94:3023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/82\">",
"      Horne A, Zheng C, Lorenz I, et al. Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. Br J Haematol 2005; 129:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/83\">",
"      Katano H, Cohen JI. Perforin and lymphohistiocytic proliferative disorders. Br J Haematol 2005; 128:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/84\">",
"      Kogawa K, Lee SM, Villanueva J, et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 2002; 99:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/85\">",
"      Aric&ograve; M, Allen M, Brusa S, et al. Haemophagocytic lymphohistiocytosis: proposal of a diagnostic algorithm based on perforin expression. Br J Haematol 2002; 119:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/86\">",
"      Feldmann J, Le Deist F, Ouach&eacute;e-Chardin M, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol 2002; 117:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/87\">",
"      Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003; 115:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/88\">",
"      Neeft M, Wieffer M, de Jong AS, et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 2005; 16:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/89\">",
"      Barrat FJ, Le Deist F, Benkerrou M, et al. Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci U S A 1999; 96:8645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/90\">",
"      Zaitsu M, Yamamoto K, Ishii E, et al. High frequency of QPY allele and linkage disequilibrium of granzyme-B in Epstein-Barr-virus-associated hemophagocytic lymphohistiocytosis. Tissue Antigens 2004; 64:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/91\">",
"      Fadeel B, Orrenius S, Henter JI. Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients. Br J Haematol 1999; 106:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/92\">",
"      Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 2002; 38:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/93\">",
"      Ohadi M, Lalloz MR, Sham P, et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 1999; 64:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/94\">",
"      G&ouml;ransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, et al. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet 2001; 68:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/95\">",
"      zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005; 14:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/96\">",
"      Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child 2011; 96:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/97\">",
"      Horne A, Ramme KG, Rudd E, et al. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol 2008; 143:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/98\">",
"      Zur Stadt U, Beutel K, Kolberg S, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat 2006; 27:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/99\">",
"      Molleran Lee S, Villanueva J, Sumegi J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet 2004; 41:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/100\">",
"      Ueda I, Morimoto A, Inaba T, et al. Characteristic perforin gene mutations of haemophagocytic lymphohistiocytosis patients in Japan. Br J Haematol 2003; 121:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/101\">",
"      Lee SM, Sumegi J, Villanueva J, et al. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. J Pediatr 2006; 149:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/102\">",
"      Busiello R, Adriani M, Locatelli F, et al. Atypical features of familial hemophagocytic lymphohistiocytosis. Blood 2004; 103:4610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/103\">",
"      Muralitharan S, Al Lamki Z, Dennison D, et al. An inframe perforin gene deletion in familial hemophagocytic lymphohistiocytosis is associated with perforin expression. Am J Hematol 2005; 78:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/104\">",
"      Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood 2005; 105:4700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/105\">",
"      Trambas C, Gallo F, Pende D, et al. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood 2005; 106:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/106\">",
"      Voskoboinik I, Thia MC, De Bono A, et al. The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene. J Exp Med 2004; 200:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/107\">",
"      Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest 2006; 116:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/108\">",
"      Ueda I, Ishii E, Morimoto A, et al. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr Blood Cancer 2006; 46:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/109\">",
"      Ueda I, Kurokawa Y, Koike K, et al. Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol 2007; 82:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/110\">",
"      Meeths M, Chiang SC, Wood SM, et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood 2011; 118:5783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/111\">",
"      Rudd E, G&ouml;ransdotter Ericson K, Zheng C, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet 2006; 43:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/112\">",
"      Marsh RA, Satake N, Biroschak J, et al. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer 2010; 55:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/113\">",
"      Bryceson YT, Rudd E, Zheng C, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 2007; 110:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/114\">",
"      zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet 2009; 85:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/115\">",
"      C&ocirc;te M, M&eacute;nager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest 2009; 119:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/116\">",
"      Meeths M, Entesarian M, Al-Herz W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood 2010; 116:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/117\">",
"      Sandrock K, Nakamura L, Vraetz T, et al. Platelet secretion defect in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL-5). Blood 2010; 116:6148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/118\">",
"      Pagel J, Beutel K, Lehmberg K, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood 2012; 119:6016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/119\">",
"      Marsh RA, Madden L, Kitchen BJ, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010; 116:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/120\">",
"      Yoshiyama M, Kounami S, Nakayama K, et al. Cytotoxic T-lymphocyte-associated antigen 4 gene polymorphisms in Japanese children with infection-associated hemophagocytic lymphohistiocytosis. Acta Haematol 2010; 123:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/121\">",
"      Imashuku S, Hibi S, Tabata Y, et al. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 32 cases. Leuk Lymphoma 2000; 37:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/122\">",
"      Fitzgerald NE, MacClain KL. Imaging characteristics of hemophagocytic lymphohistiocytosis. Pediatr Radiol 2003; 33:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/123\">",
"      Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis 2003; 36:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/124\">",
"      Ost A, Nilsson-Ardnor S, Henter JI. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology 1998; 32:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/125\">",
"      Stapp J, Wilkerson S, Stewart D, et al. Fulminant neonatal liver failure in siblings: probable congenital hemophagocytic lymphohistiocytosis. Pediatr Dev Pathol 2006; 9:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/126\">",
"      Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002; 44:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/127\">",
"      Nahum E, Ben-Ari J, Stain J, Schonfeld T. Hemophagocytic lymphohistiocytic syndrome: Unrecognized cause of multiple organ failure. Pediatr Crit Care Med 2000; 1:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/128\">",
"      Thaunat O, Delahousse M, Fakhouri F, et al. Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int 2006; 69:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/129\">",
"      Rooms L, Fitzgerald N, McClain KL. Hemophagocytic lymphohistiocytosis masquerading as child abuse: presentation of three cases and review of central nervous system findings in hemophagocytic lymphohistiocytosis. Pediatrics 2003; 111:e636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/130\">",
"      Rostasy K, Kolb R, Pohl D, et al. CNS disease as the main manifestation of hemophagocytic lymphohistiocytosis in two children. Neuropediatrics 2004; 35:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/131\">",
"      Hymel KP, Abshire TC, Luckey DW, Jenny C. Coagulopathy in pediatric abusive head trauma. Pediatrics 1997; 99:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/132\">",
"      Haddad E, Sulis ML, Jabado N, et al. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood 1997; 89:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/133\">",
"      Deiva K, Mahlaoui N, Beaudonnet F, et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology 2012; 78:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/134\">",
"      Feldmann J, M&eacute;nasch&eacute; G, Callebaut I, et al. Severe and progressive encephalitis as a presenting manifestation of a novel missense perforin mutation and impaired cytolytic activity. Blood 2005; 105:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/135\">",
"      De Armas R, Sindou P, Gelot A, et al. Demyelinating peripheral neuropathy associated with hemophagocytic lymphohistiocytosis. An immuno-electron microscopic study. Acta Neuropathol 2004; 108:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/136\">",
"      Henter JI, Nennesmo I. Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J Pediatr 1997; 130:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/137\">",
"      Horne A, Trottestam H, Aric&ograve; M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 2008; 140:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/138\">",
"      de Kerguenec C, Hillaire S, Molini&eacute; V, et al. Hepatic manifestations of hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol 2001; 96:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/139\">",
"      Danhaive O, Caniglia M, Devito R, et al. Neonatal liver failure and haemophagocytic lymphohistiocytosis caused by a new perforin mutation. Acta Paediatr 2010; 99:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/140\">",
"      Chen JH, Fleming MD, Pinkus GS, et al. Pathology of the liver in familial hemophagocytic lymphohistiocytosis. Am J Surg Pathol 2010; 34:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/141\">",
"      Esumi N, Ikushima S, Hibi S, et al. High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome. Cancer 1988; 61:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/142\">",
"      Okamoto M, Yamaguchi H, Isobe Y, et al. Analysis of triglyceride value in the diagnosis and treatment response of secondary hemophagocytic syndrome. Intern Med 2009; 48:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/143\">",
"      Gupta A, Weitzman S, Abdelhaleem M. The role of hemophagocytosis in bone marrow aspirates in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/144\">",
"      Henter JI, Samuelsson-Horne A, Aric&ograve; M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002; 100:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/145\">",
"      Sneller MC, Wang J, Dale JK, et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/146\">",
"      Fadeel B, Orrenius S, Henter JI. Familial hemophagocytic lymphohistiocytosis: too little cell death can seriously damage your health. Leuk Lymphoma 2001; 42:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/147\">",
"      Suzuki N, Morimoto A, Ohga S, et al. Characteristics of hemophagocytic lymphohistiocytosis in neonates: a nationwide survey in Japan. J Pediatr 2009; 155:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/148\">",
"      Lim MK, Lee CK, Ju YS, et al. Serum ferritin as a serologic marker of activity in systemic lupus erythematosus. Rheumatol Int 2001; 20:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/149\">",
"      Lambotte O, Cacoub P, Costedoat N, et al. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 2003; 30:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/150\">",
"      Fardet L, Coppo P, Kettaneh A, et al. Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis Rheum 2008; 58:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/151\">",
"      Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/152\">",
"      Lin TF, Ferlic-Stark LL, Allen CE, et al. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 2011; 56:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/153\">",
"      Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 1995; 86:4706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/154\">",
"      Honda K, Ohga S, Takada H, et al. Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation? Int J Hematol 2000; 72:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/155\">",
"      Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005; 74:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/156\">",
"      Thompson PA, Allen CE, Horton T, et al. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2009; 52:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/157\">",
"      Imashuku S, Kuriyama K, Sakai R, et al. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol 2003; 41:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/158\">",
"      Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 2004; 89:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/159\">",
"      Ardeshna KM, Hollifield J, Chessells JM, et al. Outcome for children after failed transplant for primary haemophagocytic lymphohistiocytosis. Br J Haematol 2001; 115:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/160\">",
"      Trottestam H, Horne A, Aric&ograve; M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011; 118:4577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/161\">",
"      Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/162\">",
"      Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/163\">",
"      Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood 1999; 93:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/164\">",
"      Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006; 107:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/165\">",
"      Horne A, Janka G, Maarten Egeler R, et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 2005; 129:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/166\">",
"      Marsh RA, Jordan MB, Filipovich AH. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol 2011; 154:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/167\">",
"      Ouach&eacute;e-Chardin M, Elie C, de Saint Basile G, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 2006; 117:e743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/168\">",
"      Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2008; 42:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/169\">",
"      Sparber-Sauer M, H&ouml;nig M, Schulz AS, et al. Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/170\">",
"      Cooper N, Rao K, Goulden N, et al. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant 2008; 42 Suppl 2:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/171\">",
"      Marsh RA, Vaughn G, Kim MO, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010; 116:5824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/172\">",
"      Buyse S, Teixeira L, Galicier L, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med 2010; 36:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/173\">",
"      &Aacute;lvarez-Cardona A, Rodr&iacute;guez-Lozano AL, Blancas-Galicia L, et al. Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. J Clin Immunol 2012; 32:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/174\">",
"      Lin CI, Yu HH, Lee JH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 2012; 31:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/175\">",
"      Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol 2011; 33:35.",
"     </a>",
"    </li>",
"    <li>",
"     www.survivorshipguidelines.org (Accessed on August 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/177\">",
"      Mahlaoui N, Ouach&eacute;e-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 2007; 120:e622.",
"     </a>",
"    </li>",
"    <li>",
"     Hybrid Immunotherapy for HLH Study: file://clinicaltrials.gov/ct2/results?term=NCT01104025 (Accessed on February 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/179\">",
"      Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010; 22:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/180\">",
"      Billiau AD, Roskams T, Van Damme-Lombaerts R, et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 2005; 105:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/181\">",
"      Hazen MM, Woodward AL, Hofmann I, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008; 58:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/182\">",
"      Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/183\">",
"      Ramanan AV, Rosenblum ND, Feldman BM, et al. Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/184\">",
"      Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/185\">",
"      Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007; 56:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/186\">",
"      Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/187\">",
"      Grom AA, Villanueva J, Lee S, et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/188\">",
"      Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7:R30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/189\">",
"      ten Cate R, Brinkman DM, van Rossum MA, et al. Macrophage activation syndrome after autologous stem cell transplantation for systemic juvenile idiopathic arthritis. Eur J Pediatr 2002; 161:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/190\">",
"      Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003; 30:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/191\">",
"      Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/192\">",
"      Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/5/41050/abstract/193\">",
"      Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl 2006; 95:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8384 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41050=[""].join("\n");
var outline_f40_5_41050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17796965\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H526310\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSOCIATED ILLNESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Familial HLH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19714867\">",
"      HLH in adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12959587\">",
"      - Underlying genetic defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19079095\">",
"      Cytokine levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Natural killer cell and cytotoxic T cell activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Perforin expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Perforin (PRF1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Munc 13-4 (UNC13D)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Syntaxin 11 (STX11)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Munc 18-2 (STXBP2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19715226\">",
"      - XIAP (BIRC4)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19715234\">",
"      - Cytotoxic T-lymphocyte-associated antigen 4 and HLH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Associated genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL AND PATHOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HLH simulating other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pathologic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Ferritin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Specialized testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      HLH-94 protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4600202\">",
"      - Long-term results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19767724\">",
"      Reduced-intensity transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      HLH-2004 protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13762518\">",
"      - Use of cyclosporin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Indications and general supportive care issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2011387\">",
"      - Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other treatment approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MACROPHAGE ACTIVATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17796965\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17796972\">",
"      When to suspect and diagnose HLH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17796979\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17796986\">",
"      Treatment of HLH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8384|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?16/42/17071\" title=\"algorithm 1\">",
"      Algorithm for the treatment of HLH and MAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8384|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/30/17890\" title=\"picture 1\">",
"      Hemophagocytic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8384|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/0/25612\" title=\"table 1\">",
"      Criteria for HLH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/40/22155\" title=\"table 2\">",
"      Diagnosis of X linked LPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35126?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10473?source=related_link\">",
"      Infectious causes of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39994?source=related_link\">",
"      Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=related_link\">",
"      Syndromic immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33384?source=related_link\">",
"      X-linked lymphoproliferative disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_5_41051="Characteristics of theophylline";
var content_f40_5_41051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absorption characteristics of selected slow-release formulations of theophylline marketed in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Formulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to peak serum",
"concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theo-24",
"       </td>",
"       <td>",
"        Variable depending on whether taken in the morning",
"after an overnight fast, after breakfast, or in the evening.",
"       </td>",
"       <td>",
"        Incomplete absorption occurs when taken after an",
"overnight fast; pH-dependent dissolution causes much more rapid (ie,",
"dose-dumping) and complete absorption when taken after food or in the",
"evening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generic SR tablets",
"       </td>",
"       <td>",
"        3 to 7 hours after morning dose when given every 12",
"hours.",
"       </td>",
"       <td>",
"        Scored tablets can be split without affecting",
"absorption characteristics; complete absorption occurs in the presence",
"or absence of food.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generic SR capsules",
"       </td>",
"       <td>",
"        3 to 7 hours after morning dose when given every 12",
"hours.",
"       </td>",
"       <td>",
"        Can be opened and sprinkled on a spoonful of soft food",
"for children who cannot swallow the capsule; contents must be swallowed",
"without chewing; complete absorption occurs in the presence or absence",
"of food.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uniphyl",
"       </td>",
"       <td>",
"        8 to 12 hours after once-daily evening dose.",
"       </td>",
"       <td>",
"        Incomplete absorption occurs when taken after overnight",
"fast; more complete absorption occurs when taken after food or in the",
"evening.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The times selected for this table represent the times for a reasonable approximation of the peak serum concentration at the dosing interval most commonly used for the product.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Weinberger, M, Hendeles, L, N Engl J Med 1996; 334:1380.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41051=[""].join("\n");
var outline_f40_5_41051=null;
var title_f40_5_41052="Incubation period for rash II";
var content_f40_5_41052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incubation period for infectious diseases associated with fever and rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent/disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma pneumoniae",
"       </td>",
"       <td>",
"        7-28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria meningitidis",
"       </td>",
"       <td>",
"        1-10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onchocerciasis",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"       <td>",
"        7-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reiter's syndrome",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relapsing fever",
"       </td>",
"       <td>",
"        4-18 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatic fever",
"       </td>",
"       <td>",
"        7-35 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsialpox, Rickettsia akari",
"       </td>",
"       <td>",
"        10-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rocky Mountain spotted fever, Rickettsia rickettsii",
"       </td>",
"       <td>",
"        2-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Roseola infantum",
"       </td>",
"       <td>",
"        5-15 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella",
"       </td>",
"       <td>",
"        5-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubeola",
"       </td>",
"       <td>",
"        10-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella typhi (enteric fever)",
"       </td>",
"       <td>",
"        3-60 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spirillum minus",
"       </td>",
"       <td>",
"        7-24 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sporothrix schenckii",
"       </td>",
"       <td>",
"        7-30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcal toxic shock syndrome",
"       </td>",
"       <td>",
"        2 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptobacillus moniliformis",
"       </td>",
"       <td>",
"        3-22 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"       <td>",
"        9-90 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma gondii",
"       </td>",
"       <td>",
"        4-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trypanosoma cruzi",
"       </td>",
"       <td>",
"        5-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tularemia",
"       </td>",
"       <td>",
"        1-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhus: endemic flea-borne, Rickettsia typhi",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhus: epidemic louse-borne, Rickettsia prowazekii",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhus: scrub, Rickettsia orientalis/Rickettsia tsutsugamushi",
"       </td>",
"       <td>",
"        6-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibrio vulnificus",
"       </td>",
"       <td>",
"        1-4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis",
"       </td>",
"       <td>",
"        2-8 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Sanders, CV. Diagnosis of the patient with&nbsp;fever and rash. In: The Skin and Infection: A Color Atlas and Text,&nbsp;Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41052=[""].join("\n");
var outline_f40_5_41052=null;
var title_f40_5_41053="NYHA CABG outcome MV surgery";
var content_f40_5_41053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Survival after mitral valve surgery is better patients in NYHA class I/II independent of CABG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-term patient survival after mitral valve surgery for chronic mitral regurgitation is better in those in NYHA class I/II compared to those in NYHA class III/IV at the time of surgery. The benefit is independent of whether or not coronary artery bypass grafting (CABG) is also performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Circulation 1999; 99:400.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41053=[""].join("\n");
var outline_f40_5_41053=null;
var title_f40_5_41054="CDC algorithm for screening for GBS in preterm PROM";
var content_f40_5_41054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CDC algorithm for screening for GBS in PROM before 37 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CDC: Centers for Disease Control and Prevention; GBS: Group B streptococcus; PROM: premature rupture of membranes.",
"     <br>",
"      * If patient has undergone vaginal-rectal GBS culture within the preceding 5 weeks, the results of that culture should guide management. GBS-colonized women should receive intrapartum antibiotic prophylaxis. No antibiotics are indicated for GBS prophylaxis if a vaginal-rectal screen within 5 weeks was negative.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Antibiotics given for latency in the setting of pPROM that include ampicillin 2 g intravenously (IV) once, followed by 1 g IV every 6 hours for at least 48 hours are adequate for GBS prophylaxis. If other regimens are used, GBS prophylaxis should be initiated in addition.",
"       <br>",
"        &Delta; GBS prophylaxis should be discontinued at 48 hours for women with pPROM who are not in labor. If results from a GBS screen performed on admission become available during the 48-hour period and are negative, GBS prophylaxis should be discontinued at that time.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Unless subsequent GBS culture prior to delivery is positive.",
"         <br>",
"          &sect; A negative GBS screen is considered valid for 5 weeks. If a patient with pPROM is entering labor and had a negative GBS screen &gt;5 weeks prior, she should be rescreened and managed according to this algorithm at that time.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010. MMWR 2010; 59:No. RR-10.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41054=[""].join("\n");
var outline_f40_5_41054=null;
var title_f40_5_41055="Survival by recipient age";
var content_f40_5_41055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Kaplan-Meier survival by age group for adult lung transplantations performed between January 1990 and June 2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart-Lung transplant report-2007. J Heart Lung Transplant 2007; 26:782. Copyright &copy; 2007 Elsevier.",
"     <br>",
"      For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled \"ADULT LUNG TRANSPLANTATION\" Kaplan-Meier Survival by Age Group (Transplants: January 1990 &ndash; June 2009)\" at:",
"      <a href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\" target=\"_blank\">",
"       file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_5_41055=[""].join("\n");
var outline_f40_5_41055=null;
